

Vicente Soriano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4609580/publications.pdf>

Version: 2024-02-01

806
papers

32,105
citations

5896

81
h-index

10158

140
g-index

859
all docs

859
docs citations

859
times ranked

18851
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. New England Journal of Medicine, 2003, 349, 1993-2003. | 27.0 | 1,560 |
| 2 | Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 339-354. | 27.0 | 699 |
| 3 | Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. Aids, 1999, 13, 1763-1769. | 2.2 | 540 |
| 4 | Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 355-365. | 27.0 | 498 |
| 5 | Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet, The, 2010, 376, 367-387. | 13.7 | 431 |
| 6 | Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. Journal of Infectious Diseases, 2005, 192, 958-966. | 4.0 | 385 |
| 7 | Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2005, 192, 992-1002. | 4.0 | 362 |
| 8 | Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408. | 3.7 | 341 |
| 9 | Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62. | 13.7 | 303 |
| 10 | Care of patients coinfecting with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. Aids, 2007, 21, 1073-1089. | 2.2 | 295 |
| 11 | Short Communication: Transmission of Hepatitis B Viruses with Lamivudine Resistance Mutations in Newly Diagnosed HIV Individuals. AIDS Research and Human Retroviruses, 2009, 25, 1273-1276. | 1.1 | 295 |
| 12 | Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C: A European Collaborative Study. Clinical Infectious Diseases, 2004, 38, 128-133. | 5.8 | 291 |
| 13 | Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. Aids, 2002, 16, 813-828. | 2.2 | 280 |
| 14 | Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration. PLoS Medicine, 2005, 2, e112. | 8.4 | 262 |
| 15 | Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids, 2009, 23, 689-696. | 2.2 | 250 |
| 16 | Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. Journal of Antimicrobial Chemotherapy, 2008, 62, 1-4. | 3.0 | 249 |
| 17 | European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Medicine, 2008, 9, 82-88. | 2.2 | 222 |
| 18 | Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. Clinical Infectious Diseases, 2009, 48, e108-e116. | 5.8 | 221 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases</i> , 2011, 11, 394-407. | 9.1 | 218 |
| 20 | Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001, 96, 179-183. | 0.4 | 215 |
| 21 | Faldaprevir and Deleobuvir for HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2013, 369, 630-639. | 27.0 | 215 |
| 22 | Hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2004, 18, 2285-2293. | 2.2 | 213 |
| 23 | Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1467-1471. | 1.1 | 197 |
| 24 | Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. <i>Clinical Infectious Diseases</i> , 2005, 41, 1772-1782. | 5.8 | 197 |
| 25 | Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. <i>Clinical Infectious Diseases</i> , 2010, 50, 605-612. | 5.8 | 196 |
| 26 | Care of patients with hepatitis C and HIV co-infection. <i>Aids</i> , 2004, 18, 1-12. | 2.2 | 194 |
| 27 | Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810. | 8.4 | 188 |
| 28 | Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1996, 23, 585-591. | 5.8 | 187 |
| 29 | Chemoprophylaxis with Tenofovir Disoproxil Fumarate Provided Partial Protection against Infection with Simian Human Immunodeficiency Virus in Macaques Given Multiple Virus Challenges. <i>Journal of Infectious Diseases</i> , 2006, 194, 904-911. | 4.0 | 185 |
| 30 | Pegylated IFN- α 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2003, 17, 1023-1028. | 2.2 | 183 |
| 31 | Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 972-982. | 1.1 | 183 |
| 32 | Hepatotoxicity after introduction of highly active antiretroviral therapy. <i>Aids</i> , 1998, 12, 1256. | 2.2 | 180 |
| 33 | Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. <i>Annals of Internal Medicine</i> , 2013, 159, 86-96. | 3.9 | 179 |
| 34 | Viral hepatitis and HIV co-infection. <i>Antiviral Research</i> , 2010, 85, 303-315. | 4.1 | 177 |
| 35 | Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects. <i>Clinical Infectious Diseases</i> , 2005, 40, 1358-1361. | 5.8 | 176 |
| 36 | Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. <i>Aids</i> , 2001, 15, 309-320. | 2.2 | 169 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Antiretroviral drugs and liver injury. <i>Aids</i> , 2008, 22, 1-13. | 2.2 | 163 |
| 38 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e754-e764. | 5.8 | 160 |
| 39 | Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. <i>European Journal of Epidemiology</i> , 1999, 15, 1-4. | 5.7 | 158 |
| 40 | Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2007, 196, 670-676. | 4.0 | 157 |
| 41 | HIV entry inhibitors: mechanisms of action and resistance pathways. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 619-627. | 3.0 | 156 |
| 42 | Liver toxicity caused by nevirapine. <i>Aids</i> , 2002, 16, 290-291. | 2.2 | 151 |
| 43 | New Therapies for Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2009, 48, 313-320. | 5.8 | 150 |
| 44 | Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <i>Aids</i> , 2008, 22, 1399-1410. | 2.2 | 149 |
| 45 | Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. <i>Journal of Infectious Diseases</i> , 2008, 198, 1337-1344. | 4.0 | 145 |
| 46 | Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. <i>Aids</i> , 2000, 14, 807-812. | 2.2 | 143 |
| 47 | Analyzing Sleep Abnormalities in HIV-Infected Patients Treated with Efavirenz. <i>Clinical Infectious Diseases</i> , 2004, 38, 430-432. | 5.8 | 128 |
| 48 | Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. <i>Aids</i> , 2007, 21, 41-46. | 2.2 | 127 |
| 49 | Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. <i>Aids</i> , 2011, 25, 399-409. | 2.2 | 126 |
| 50 | Protease sequences from HIV-1 group M subtypes A1-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naïve individuals worldwide. <i>Aids</i> , 2000, 14, 1489-1495. | 2.2 | 125 |
| 51 | Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010, 24, 1064-1066. | 2.2 | 120 |
| 52 | Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809. | 8.4 | 119 |
| 53 | Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus Type I from a single donor. <i>Transplantation</i> , 2003, 75, 102-104. | 1.0 | 116 |
| 54 | Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1. <i>Clinical Infectious Diseases</i> , 2006, 42, 291-295. | 5.8 | 116 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Hepatitis B virus escape mutants induced by antiviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 766-768. | 3.0 | 115 |
| 56 | Renal toxicity associated with tenofovir use. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 545-559. | 2.4 | 111 |
| 57 | Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 383-386. | 2.2 | 109 |
| 58 | Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. <i>Aids</i> , 2005, 19, 2117-2125. | 2.2 | 109 |
| 59 | Mutations affecting the replication capacity of the hepatitis B virus. <i>Journal of Viral Hepatitis</i> , 2006, 13, 427-434. | 2.0 | 109 |
| 60 | Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine. <i>HIV Clinical Trials</i> , 2003, 4, 115-120. | 2.0 | 106 |
| 61 | Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3860-3868. | 3.9 | 103 |
| 62 | Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. <i>Journal of Infectious Diseases</i> , 2011, 204, 145-153. | 4.0 | 102 |
| 63 | Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. <i>Aids</i> , 2002, 16, 2352-2354. | 2.2 | 101 |
| 64 | Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. <i>EMBO Journal</i> , 2000, 19, 5752-5761. | 7.8 | 100 |
| 65 | Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes. <i>Journal of Clinical Microbiology</i> , 2008, 46, 887-891. | 3.9 | 98 |
| 66 | Phylogenetic relationship and geographic distribution of multiple human T-cell lymphotropic virus type II subtypes. <i>Journal of Virology</i> , 1995, 69, 621-632. | 3.4 | 98 |
| 67 | Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity. <i>International Journal of Infectious Diseases</i> , 2020, 97, 290-292. | 3.3 | 97 |
| 68 | Gastrointestinal Leishmaniasis in Human Immunodeficiency Virus-Infected Patients: Report of Five Cases and Review. <i>Clinical Infectious Diseases</i> , 1994, 19, 48-53. | 5.8 | 96 |
| 69 | Tenofovir-related nephrotoxicity in HIV-infected patients. <i>Aids</i> , 2004, 18, 960-963. | 2.2 | 96 |
| 70 | Chronic Hepatitis E in HIV Patients: Rapid Progression to Cirrhosis and Response to Oral Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 57, 465-468. | 5.8 | 96 |
| 71 | Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. <i>Journal of Viral Hepatitis</i> , 2008, 15, 165-172. | 2.0 | 94 |
| 72 | Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. <i>Aids</i> , 2004, 18, 1109-1116. | 2.2 | 93 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Main differences between the first and second waves of COVID-19 in Madrid, Spain. International Journal of Infectious Diseases, 2021, 105, 374-376. | 3.3 | 92 |
| 74 | Hepatotoxicity of Antiretrovirals. Drug Safety, 2005, 28, 53-66. | 3.2 | 91 |
| 75 | Management of chronic hepatitis C in HIV-infected patients. Aids, 1999, 13, 539-546. | 2.2 | 90 |
| 76 | Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. , 2000, 61, 111-116. | | 89 |
| 77 | Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial. Antiviral Therapy, 2011, 16, 339-348. | 1.0 | 89 |
| 78 | Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. Journal of Viral Hepatitis, 2008, 15, 427-433. | 2.0 | 87 |
| 79 | Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. Journal of Antimicrobial Chemotherapy, 2008, 61, 699-704. | 3.0 | 87 |
| 80 | Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected Patients. Clinical Infectious Diseases, 2014, 58, 1549-1553. | 5.8 | 85 |
| 81 | Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. Aids, 2010, 24, 1171-1176. | 2.2 | 84 |
| 82 | Directly acting antivirals against hepatitis C virus. Journal of Antimicrobial Chemotherapy, 2011, 66, 1673-1686. | 3.0 | 81 |
| 83 | Emergence of Drug Resistance Mutations in Human Immunodeficiency Virus Type 2-Infected Subjects Undergoing Antiretroviral Therapy. Journal of Clinical Microbiology, 2000, 38, 1370-1374. | 3.9 | 81 |
| 84 | CD38 Expression on CD8 T Lymphocytes as a Marker of Residual Virus Replication in Chronically HIV-Infected Patients Receiving Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 227-233. | 1.1 | 80 |
| 85 | Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2006, 57, 709-713. | 3.0 | 79 |
| 86 | Hepatitis delta in HIV-infected individuals in Europe. Aids, 2011, 25, 1987-1992. | 2.2 | 79 |
| 87 | Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent. Antimicrobial Agents and Chemotherapy, 2006, 50, 694-701. | 3.2 | 78 |
| 88 | Management of chronic hepatitis B and C in HIV-coinfected patients. Journal of Antimicrobial Chemotherapy, 2006, 57, 815-818. | 3.0 | 78 |
| 89 | Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. Journal of Antimicrobial Chemotherapy, 2008, 62, 1174-1180. | 3.0 | 78 |
| 90 | Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. Journal of Antimicrobial Chemotherapy, 2007, 59, 698-704. | 3.0 | 76 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005, 19, 569-575. | 2.2 | 75 |
| 92 | Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. <i>Aids</i> , 2000, 14, 2153-2157. | 2.2 | 74 |
| 93 | Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. <i>Aids</i> , 2011, 25, 73-79. | 2.2 | 74 |
| 94 | Is natural conception a valid option for HIV-serodiscordant couples?. <i>Human Reproduction</i> , 2007, 22, 2353-2358. | 0.9 | 72 |
| 95 | Lack of "occult" hepatitis B virus infection in HIV-infected patients. <i>Aids</i> , 2002, 16, 2099-2101. | 2.2 | 72 |
| 96 | HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. <i>Aids</i> , 2006, 20, 1359-1367. | 2.2 | 71 |
| 97 | Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 200-205. | 3.0 | 70 |
| 98 | Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. <i>Journal of Viral Hepatitis</i> , 2011, 18, 11-16. | 2.0 | 67 |
| 99 | Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients. <i>HIV Clinical Trials</i> , 2004, 5, 201-205. | 2.0 | 66 |
| 100 | Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 679-688. | 1.8 | 66 |
| 101 | Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1031-1036. | 3.9 | 66 |
| 102 | Population Pharmacokinetic Modeling of the Association between 63396C>T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5242-5250. | 3.2 | 66 |
| 103 | The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. <i>AIDS Reviews</i> , 2021, 23, 40-47. | 1.0 | 66 |
| 104 | Mycosis fungoides and Sezary syndrome are not associated with HTLV-1 infection: an international study. <i>British Journal of Haematology</i> , 1997, 98, 927-933. | 2.5 | 65 |
| 105 | Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. <i>Journal of Viral Hepatitis</i> , 2004, 11, 2-17. | 2.0 | 65 |
| 106 | Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. <i>Journal of Medical Virology</i> , 2004, 74, 21-28. | 5.0 | 64 |
| 107 | Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide. <i>Aids</i> , 2004, 18, 1137-1146. | 2.2 | 64 |
| 108 | Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. <i>Aids</i> , 2006, 20, 1951-1954. | 2.2 | 64 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1365-1373. | 3.0 | 64 |
| 110 | Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1006-1010. | 3.0 | 64 |
| 111 | Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. <i>Aids</i> , 2012, 26, 1387-1392. | 2.2 | 64 |
| 112 | Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 1998, 72, 9002-9015. | 3.4 | 64 |
| 113 | Management of patients co-infected with hepatitis B virus and HIV. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 374-382. | 9.1 | 63 |
| 114 | High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1486-1492. | 3.0 | 63 |
| 115 | Introduction of HIV drug-resistance testing in clinical practice. <i>Aids</i> , 1999, 13, 1007-1014. | 2.2 | 62 |
| 116 | Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001, 96, 179-183. | 0.4 | 62 |
| 117 | Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2873-2878. | 3.2 | 62 |
| 118 | Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , 2012, 26, 1917-1926. | 2.2 | 62 |
| 119 | Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. <i>Journal of Hepatology</i> , 1999, 31, 119-123. | 3.7 | 61 |
| 120 | Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. <i>Aids</i> , 2001, 15, 1701-1706. | 2.2 | 61 |
| 121 | High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. <i>Aids</i> , 2002, 16, 1163-1170. | 2.2 | 61 |
| 122 | Hepatitis C viraemia in HIV/HCV co-infected patients having immune restoration with highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 212. | 2.2 | 61 |
| 123 | Characterization of the Reverse Transcriptase of a Human Immunodeficiency Virus Type 1 Group O Isolate. <i>Virology</i> , 1997, 236, 364-373. | 2.4 | 60 |
| 124 | Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. <i>Clinical Immunology</i> , 2011, 139, 110-114. | 3.2 | 60 |
| 125 | Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. <i>Journal of Infection</i> , 2016, 72, 587-596. | 3.3 | 60 |
| 126 | The global spread of HIV-1 subtype B epidemic. <i>Infection, Genetics and Evolution</i> , 2016, 46, 169-179. | 2.3 | 60 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Prediction of Virological Response to Lopinavir/Ritonavir Using the Genotypic Inhibitory Quotient. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 275-278. | 1.1 | 59 |
| 128 | Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865. | 2.2 | 59 |
| 129 | SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals. <i>HIV Clinical Trials</i> , 2002, 3, 186-194. | 2.0 | 58 |
| 130 | Increase of Non-B Subtypes and Recombinants Among Newly Diagnosed HIV-1 Native Spaniards and Immigrants in Spain. <i>Current HIV Research</i> , 2008, 6, 327-334. | 0.5 | 58 |
| 131 | Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. <i>Aids</i> , 2002, 16, 245-249. | 2.2 | 57 |
| 132 | Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. <i>Aids</i> , 2008, 22, 15-21. | 2.2 | 57 |
| 133 | Hepatitis C therapy with HCV NS5B polymerase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1161-1170. | 1.8 | 57 |
| 134 | Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV–positive patients. <i>Journal of Viral Hepatitis</i> , 2016, 23, 47-52. | 2.0 | 57 |
| 135 | Treatment of Chronic Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Present and Future. <i>Clinical Infectious Diseases</i> , 2003, 37, 1678-1685. | 5.8 | 56 |
| 136 | Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. <i>Journal of Clinical Virology</i> , 2004, 31, 215-220. | 3.1 | 56 |
| 137 | Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2918-2923. | 3.9 | 56 |
| 138 | Pharmacogenetics of tenofovir treatment. <i>Pharmacogenomics</i> , 2009, 10, 1675-1685. | 1.3 | 56 |
| 139 | Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. <i>Clinical Infectious Diseases</i> , 2010, 51, 1209-1216. | 5.8 | 56 |
| 140 | Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. <i>Aids</i> , 2014, 28, 2389-2394. | 2.2 | 56 |
| 141 | Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. <i>Journal of Clinical Virology</i> , 2005, 34, 295-301. | 3.1 | 55 |
| 142 | Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. <i>Journal of Clinical Virology</i> , 2006, 36, 264-271. | 3.1 | 55 |
| 143 | Overview of the pharmacogenetics of HIV therapy. <i>Pharmacogenomics Journal</i> , 2006, 6, 234-245. | 2.0 | 55 |
| 144 | Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1629-1636. | 4.0 | 55 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. <i>Aids</i> , 2013, 27, 81-85. | 2.2 | 55 |
| 146 | Comparative Performance of Three Viral Load Assays on Human Immunodeficiency Virus Type 1 (HIV-1) Isolates Representing Group M (Subtypes A to G) and Group O: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR Version 1.5, and Quantiplex HIV-1 RNA Version 3.0. <i>Journal of Clinical Microbiology</i> , 2001, 39, 862-870. | 3.9 | 54 |
| 147 | Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 885-888. | 3.0 | 54 |
| 148 | Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 320-326. | 3.0 | 54 |
| 149 | Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. <i>Aids</i> , 2000, 14, 727-732. | 2.2 | 53 |
| 150 | Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. <i>Clinical Infectious Diseases</i> , 2005, 41, 1350-1354. | 5.8 | 53 |
| 151 | Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 694-698. | 3.0 | 53 |
| 152 | Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475. | 5.8 | 53 |
| 153 | Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients. <i>Aids</i> , 2013, 27, 181-189. | 2.2 | 53 |
| 154 | Prevention and management of treatment failure to new oral hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1215-1223. | 1.8 | 53 |
| 155 | Lack of benefit or protease inhibitors on HCV viremia in HIV- infected patients. <i>Journal of Hepatology</i> , 1998, 28, 526-527. | 3.7 | 52 |
| 156 | Are Fusion Inhibitors Active against All HIV Variants?. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 347-348. | 1.1 | 51 |
| 157 | Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3. <i>Clinical Infectious Diseases</i> , 2006, 42, 1032-1039. | 5.8 | 51 |
| 158 | Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555. | 3.0 | 51 |
| 159 | Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 543-547. | 3.0 | 51 |
| 160 | Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. <i>Aids</i> , 2002, 16, 1959-1961. | 2.2 | 51 |
| 161 | Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. <i>Journal of Medical Virology</i> , 2009, 81, 763-767. | 5.0 | 50 |
| 162 | Rate and Predictors of Treatment Failure to All-Oral HCV Regimens outside Clinical Trials. <i>Antiviral Therapy</i> , 2017, 22, 307-312. | 1.0 | 50 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Evaluation of performance across the dynamic range of the Abbott RealTime [®] HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. <i>Journal of Virological Methods</i> , 2007, 141, 49-57. | 2.1 | 49 |
| 164 | Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. <i>Journal of Viral Hepatitis</i> , 2009, 16, 895-896. | 2.0 | 49 |
| 165 | Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. <i>Aids</i> , 2005, 19, 221-40. | 2.2 | 49 |
| 166 | CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. <i>Aids</i> , 1994, 8, 1621. | 2.2 | 48 |
| 167 | Horizontal and Vertical Transmission of Human Immunodeficiency Virus Type 1 Dual Infections Caused by Viruses of Subtypes B and C. <i>Journal of Infectious Diseases</i> , 1998, 177, 227-231. | 4.0 | 48 |
| 168 | The effect of antiretroviral therapy on HTLV infection. <i>Virus Research</i> , 2001, 78, 93-100. | 2.2 | 48 |
| 169 | Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience. <i>Antiviral Research</i> , 2011, 90, 164-167. | 4.1 | 48 |
| 170 | Update on HIV/HCV Coinfection. <i>Current HIV/AIDS Reports</i> , 2013, 10, 226-234. | 3.1 | 48 |
| 171 | Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. <i>Aids</i> , 2002, 16, 2079-2081. | 2.2 | 48 |
| 172 | Prevalence of HIV-1 non-B subtypes, syphilis, HTLV, and hepatitis B and C viruses among immigrant sex workers in Madrid, Spain. <i>Journal of Medical Virology</i> , 2004, 74, 521-527. | 5.0 | 47 |
| 173 | Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfecting patients receiving lamivudine as part of antiretroviral therapy. <i>Aids</i> , 2008, 22, 1779-1787. | 2.2 | 47 |
| 174 | Dual antiretroviral therapy for HIV infection. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 923-932. | 2.4 | 47 |
| 175 | HIV – Causing AIDS and Death in a Seronegative Individual. <i>Vox Sanguinis</i> , 1994, 67, 410-411. | 1.5 | 46 |
| 176 | Mortality Due to Chronic Viral Liver Disease among Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2001, 33, 1793-1795. | 5.8 | 46 |
| 177 | HIV-1 subtypes in Spain: a retrospective analysis from 1995 to 2003. <i>HIV Medicine</i> , 2005, 6, 313-320. | 2.2 | 46 |
| 178 | Risk of selecting K65R in antiretroviral-naïve HIV-infected individuals with chronic hepatitis B treated with adefovir. <i>Aids</i> , 2005, 19, 2036-2038. | 2.2 | 46 |
| 179 | Level, phenotype and activation status of CD4+FoxP3+regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. <i>Clinical and Experimental Immunology</i> , 2009, 155, 35-43. | 2.6 | 46 |
| 180 | Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. <i>HIV Medicine</i> , 2013, 14, 614-623. | 2.2 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Drug interactions with new hepatitis C oral drugs. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 333-341. | 3.3 | 46 |
| 182 | Efficacy and safety of \pm -interferon treatment for chronic hepatitis C in HIV-infected patients. Journal of Infection, 1995, 31, 9-13. | 3.3 | 45 |
| 183 | Scaling up epidemics of acute hepatitis C and syphilis in <scp>HIV</scp>-infected men who have sex with men in Spain. Liver International, 2013, 33, 1357-1362. | 3.9 | 45 |
| 184 | Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS ONE, 2015, 10, e0139981. | 2.5 | 45 |
| 185 | Impact of Chronic Hepatitis C on HIV-1 Disease Progression. HIV Clinical Trials, 2004, 5, 125-131. | 2.0 | 44 |
| 186 | Short Communication: Liver Toxicity of Lopinavir-Containing Regimens in HIV-Infected Patients with or without Hepatitis C Coinfection. AIDS Research and Human Retroviruses, 2004, 20, 698-700. | 1.1 | 44 |
| 187 | Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A Inhibitor. Antiviral Therapy, 2012, 17, 921-926. | 1.0 | 44 |
| 188 | Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. Journal of Medical Virology, 2007, 79, 1040-1046. | 5.0 | 43 |
| 189 | Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Aids, 2008, 22, 367-376. | 2.2 | 43 |
| 190 | New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs, 2017, 26, 843-851. | 4.1 | 43 |
| 191 | Hepatitis C Virus (HCV) Relapses after Anti-HCV Therapy Are More Frequent in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2004, 20, 351-353. | 1.1 | 42 |
| 192 | Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. Journal of Virological Methods, 2005, 127, 54-59. | 2.1 | 42 |
| 193 | Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. Antimicrobial Agents and Chemotherapy, 2005, 49, 3997-4008. | 3.2 | 42 |
| 194 | Treatment of Chronic Hepatitis B or C in HIV-Infected Patients with Dual Viral Hepatitis. Journal of Infectious Diseases, 2007, 195, 1181-1183. | 4.0 | 42 |
| 195 | Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. Aids, 2007, 21, 1487-1490. | 2.2 | 42 |
| 196 | Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. International Journal of Antimicrobial Agents, 2002, 20, 438-443. | 2.5 | 41 |
| 197 | Changes in Mitochondrial DNA Copy Number in Blood Cells from HIV-Infected Patients Undergoing Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 271-273. | 1.1 | 41 |
| 198 | Emerging drugs for hepatitis C. Expert Opinion on Emerging Drugs, 2008, 13, 1-19. | 2.4 | 41 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | Raltegravir and Etravirine Are Active against HIV Type 1 Group O. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 225-227. | 1.1 | 41 |
| 200 | Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group. <i>Clinical Infectious Diseases</i> , 2011, 52, 1257-1266. | 5.8 | 41 |
| 201 | Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load Assay. <i>Journal of Clinical Microbiology</i> , 2012, 50, 569-572. | 3.9 | 41 |
| 202 | Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. <i>Journal of Hepatology</i> , 2013, 59, 213-220. | 3.7 | 41 |
| 203 | Hepatitis C virus resistance to the new direct-acting antivirals. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1197-1209. | 3.3 | 41 |
| 204 | Salvage Treatment with Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients Failing All Current Antiretroviral Drug Families. <i>HIV Clinical Trials</i> , 2002, 3, 304-309. | 2.0 | 40 |
| 205 | Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. <i>Journal of Hepatology</i> , 2008, 49, 323-328. | 3.7 | 40 |
| 206 | Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1493-1496. | 3.0 | 40 |
| 207 | HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. <i>Aids</i> , 2004, 18, 495-502. | 2.2 | 39 |
| 208 | Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 821-825. | 1.1 | 39 |
| 209 | Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 816-822. | 3.0 | 39 |
| 210 | Antiviral effect of raltegravir on HTLV-1 carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 218-221. | 3.0 | 39 |
| 211 | Cryptosporidiosis. <i>New England Journal of Medicine</i> , 2002, 347, 1287-1287. | 27.0 | 38 |
| 212 | HIV protease inhibitors: recent clinical trials and recommendations on use. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1615-1629. | 1.8 | 38 |
| 213 | Low-Level Exposure to HIV Induces Virus-Specific T Cell Responses and Immune Activation in Exposed HIV-Seronegative Individuals. <i>Journal of Immunology</i> , 2010, 185, 982-989. | 0.8 | 38 |
| 214 | Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 507-517. | 3.1 | 38 |
| 215 | Third wave of COVID-19 in Madrid, Spain. <i>International Journal of Infectious Diseases</i> , 2021, 107, 212-214. | 3.3 | 38 |
| 216 | The changing epidemiology of liver disease in HIV patients. <i>AIDS Reviews</i> , 2013, 15, 25-31. | 1.0 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Prevalence of HTLV infection in pregnant women in Spain. Sexually Transmitted Infections, 2000, 76, 366-370. | 1.9 | 37 |
| 218 | Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. Aids, 2008, 22, 611-616. | 2.2 | 37 |
| 219 | Natural Polymorphisms Associated with Resistance to New Antivirals against HCV in Newly Diagnosed HIV-HCV-Coinfected Patients. Antiviral Therapy, 2011, 16, 413-416. | 1.0 | 37 |
| 220 | Infection-related and -unrelated malignancies, <scp>HIV</scp> and the aging population. HIV Medicine, 2016, 17, 590-600. | 2.2 | 37 |
| 221 | Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. Aids, 2001, 15, 1894-1896. | 2.2 | 37 |
| 222 | Predictors of selection of K65R. Aids, 2004, 18, 2094-2096. | 2.2 | 36 |
| 223 | Coinfection with Hepatitis C Virus Increases Lymphocyte Apoptosis in HIV-Infected Patients. Clinical Infectious Diseases, 2006, 43, 1209-1212. | 5.8 | 36 |
| 224 | Management of Chronic Hepatitis C Virus Infection in HIV-Infected Patients. Clinical Infectious Diseases, 2008, 47, 94-101. | 5.8 | 36 |
| 225 | Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. Aids, 2008, 22, 2535-2537. | 2.2 | 36 |
| 226 | Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 457-477. | 3.3 | 36 |
| 227 | HTLV-I/II Infections in Spain. International Journal of Epidemiology, 1993, 22, 716-719. | 1.9 | 35 |
| 228 | Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients. AIDS Research and Human Retroviruses, 2007, 23, 879-885. | 1.1 | 35 |
| 229 | Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opinion on Biological Therapy, 2007, 7, 751-761. | 3.1 | 35 |
| 230 | Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. Aids, 2007, 21, 2521-2527. | 2.2 | 35 |
| 231 | Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. Journal of Viral Hepatitis, 2007, 14, 387-391. | 2.0 | 35 |
| 232 | Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV-Infected and HIV-Uninfected Patients. Clinical Infectious Diseases, 2009, 49, 1397-1401. | 5.8 | 35 |
| 233 | Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. Journal of Viral Hepatitis, 2009, 16, 790-795. | 2.0 | 35 |
| 234 | Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antiviral Therapy, 2010, 15, 881-886. | 1.0 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Efficacy and safety of rilpivirine in treatment-naïve, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2020-2028. | 3.0 | 35 |
| 236 | Hepatitis delta and HIV infection. <i>Aids</i> , 2017, 31, 875-884. | 2.2 | 35 |
| 237 | Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. <i>PLoS ONE</i> , 2014, 9, e87160. | 2.5 | 35 |
| 238 | First Case of HIV-1 Group O Infection in Spain. <i>Vox Sanguinis</i> , 1996, 71, 66-66. | 1.5 | 34 |
| 239 | Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. <i>Journal of Viral Hepatitis</i> , 2000, 7, 403-408. | 2.0 | 34 |
| 240 | Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. <i>Virus Research</i> , 2000, 66, 13-26. | 2.2 | 34 |
| 241 | Prevalence of Human Immunodeficiency Virus Type 1 (HIV-1) Non-B Subtypes in Foreigners Living in Madrid, Spain, and Comparison of the Performances of the AMPLICOR HIV-1 MONITOR Version 1.0 and the New Automated Version 1.5. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1850-1854. | 3.9 | 34 |
| 242 | Differences in Cellular Activation and Apoptosis in HIV-Infected Patients Receiving Protease Inhibitors or Nucleoside Reverse Transcriptase Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1379-1388. | 1.1 | 34 |
| 243 | Distribution of Hepatitis B Virus Genotypes in HIV-Infected Patients with Chronic Hepatitis B: Therapeutic Implications. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 657-659. | 1.1 | 34 |
| 244 | High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. <i>Aids</i> , 2010, 24, 467-469. | 2.2 | 34 |
| 245 | Noncirrhotic portal hypertension in HIV infection. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 12-18. | 3.1 | 34 |
| 246 | Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfecting patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012, 56, 788-794. | 3.7 | 34 |
| 247 | Endothelial dysfunction in HIV infection--the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages. <i>AIDS Reviews</i> , 2012, 14, 223-30. | 1.0 | 34 |
| 248 | Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naïve and Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1245-1247. | 3.9 | 33 |
| 249 | Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. <i>Journal of Medical Virology</i> , 2006, 78, 1599-1608. | 5.0 | 33 |
| 250 | Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 806-809. | 3.0 | 33 |
| 251 | Optimal use of maraviroc in clinical practice. <i>Aids</i> , 2008, 22, 2231-2240. | 2.2 | 33 |
| 252 | When and how to use maraviroc in HIV-infected patients. <i>Aids</i> , 2009, 23, 2377-2385. | 2.2 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1567-1569. | 3.0 | 33 |
| 254 | Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-co-infected patients. <i>Aids</i> , 2011, 25, 2197-2208. | 2.2 | 33 |
| 255 | Hepatitis C seroconversions in <scp>HIV</scp> infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , 2015, 35, 2384-2391. | 3.9 | 33 |
| 256 | Genetic mechanisms of resistance to NRTI and NNRTI. <i>HIV Clinical Trials</i> , 2002, 3, 237-248. | 2.0 | 32 |
| 257 | Resistance to Antiretroviral Agents in Individuals with HIV-1 Non-B Subtypes. <i>HIV Clinical Trials</i> , 2002, 3, 403-411. | 2.0 | 32 |
| 258 | Failure to Detect Human Immunodeficiency Virus Type 1 Superinfection in 28 HIV-Seroconcordant Individuals with High Risk of Reexposure to the Virus. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1026-1031. | 1.1 | 32 |
| 259 | Evidence for Differences in the Sexual Transmission Efficiency of HIV Strains with Distinct Drug Resistance Genotypes. <i>Clinical Infectious Diseases</i> , 2004, 39, 1231-1238. | 5.8 | 32 |
| 260 | Clinical benefit of interventions driven by therapeutic drug monitoring. <i>HIV Medicine</i> , 2005, 6, 360-365. | 2.2 | 32 |
| 261 | Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 537-542. | 3.7 | 32 |
| 262 | Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. <i>European Journal of Immunology</i> , 2007, 37, 501-515. | 2.9 | 32 |
| 263 | Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: Implications for HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Infection</i> , 2007, 54, 173-179. | 3.3 | 32 |
| 264 | Survival of HIV-infected patients with compensated liver cirrhosis. <i>Aids</i> , 2010, 24, 745-753. | 2.2 | 32 |
| 265 | Impact of Baseline HIV-1 Tropism on Viral Response and CD4 Cell Count Gains in HIV-Infected Patients Receiving First-line Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 139-144. | 4.0 | 32 |
| 266 | Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. <i>PLoS ONE</i> , 2012, 7, e41673. | 2.5 | 32 |
| 267 | Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. <i>Journal of Medical Virology</i> , 2000, 61, 111-6. | 5.0 | 32 |
| 268 | Evidence of Nef Truncation in Human Immunodeficiency Virus Type 2 Infection. <i>Journal of Infectious Diseases</i> , 1998, 177, 65-71. | 4.0 | 31 |
| 269 | Short Communication: Interactions between Nevirapine Plasma Levels, Chronic Hepatitis C, and the Development of Liver Toxicity in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 187-188. | 1.1 | 31 |
| 270 | First-Line Therapy and Mitochondrial Damage: Different Nucleosides, Different Findings. <i>HIV Clinical Trials</i> , 2003, 4, 11-19. | 2.0 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Antiretroviral Recommendations May Influence the Rate of Transmission of Drug-Resistant HIV Type 1. <i>Clinical Infectious Diseases</i> , 2005, 41, 227-232. | 5.8 | 31 |
| 272 | Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1409-1410. | 3.0 | 31 |
| 273 | Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2011, 18, 325-330. | 2.0 | 31 |
| 274 | Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383. | 4.0 | 31 |
| 275 | Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 739-748. | 1.8 | 31 |
| 276 | Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. <i>Aids</i> , 2002, 16, 1423-1425. | 2.2 | 31 |
| 277 | Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. <i>Aids</i> , 2002, 16, 1964-1966. | 2.2 | 31 |
| 278 | Protease Gene Analysis of HIV Type 1 Non-B Subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1395-1403. | 1.1 | 30 |
| 279 | Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3865-3866. | 3.9 | 30 |
| 280 | Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. <i>Infection, Genetics and Evolution</i> , 2007, 7, 382-390. | 2.3 | 30 |
| 281 | Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. <i>Aids</i> , 2008, 22, 2395-2398. | 2.2 | 30 |
| 282 | Seroprevalence of HTLV-1/2 Infection among Native and Immigrant Pregnant Women in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 551-554. | 1.1 | 30 |
| 283 | Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. <i>Journal of Clinical Virology</i> , 2009, 46, 173-175. | 3.1 | 30 |
| 284 | Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). <i>HIV Medicine</i> , 2011, 12, 374-382. | 2.2 | 30 |
| 285 | Inpatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 232-235. | 2.0 | 30 |
| 286 | Pharmacogenetics of hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 523-529. | 3.0 | 30 |
| 287 | Treatment failure with new hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 313-323. | 1.8 | 30 |
| 288 | Dolutegravir for the treatment of HIV-2 infection. <i>Journal of Clinical Virology</i> , 2015, 64, 12-15. | 3.1 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | Human T-lymphotropic virus type 1 infection and disease in Spain. <i>Aids</i> , 2017, 31, 1653-1663. | 2.2 | 30 |
| 290 | Recombinant Human Immunodeficiency Viruses Type 1 Circulating in Spain. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 505-511. | 1.1 | 29 |
| 291 | Natural history of Hymenoptera venom allergy in Eastern Spain. <i>Clinical and Experimental Allergy</i> , 2005, 35, 179-185. | 2.9 | 29 |
| 292 | HTLV infection among young injection and non-injection heroin users in Spain: Prevalence and correlates. <i>Journal of Clinical Virology</i> , 2006, 35, 244-249. | 3.1 | 29 |
| 293 | Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. <i>Aids</i> , 2006, 20, 1071-1074. | 2.2 | 29 |
| 294 | Profile of Patients Triply Infected with HIV and the Hepatitis B and C Viruses in the HAART Era. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 679-683. | 1.1 | 29 |
| 295 | An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHI E V 2E Quality Control Study. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3491-3497. | 3.9 | 29 |
| 296 | Drug resistance mutations in patients infected with HIV-2 living in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1484-1488. | 3.0 | 29 |
| 297 | Resistance to HIV Protease Inhibitors: Mechanisms and Clinical Consequences. <i>Current Drug Metabolism</i> , 2004, 5, 321-328. | 1.2 | 29 |
| 298 | Opportunistic Infections Shortly after Beginning Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 1998, 3, 229-231. | 1.0 | 29 |
| 299 | Management of hepatitis C in HIV-infected persons. <i>Antiviral Research</i> , 2001, 52, 189-198. | 4.1 | 28 |
| 300 | Evaluation of the Abbott LCx Quantitative Assay for Measurement of Human Immunodeficiency Virus RNA in Plasma. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1518-1521. | 3.9 | 28 |
| 301 | Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity. <i>HIV Clinical Trials</i> , 2005, 6, 197-202. | 2.0 | 28 |
| 302 | Measurement of Ribavirin Plasma Concentrations by High-performance Liquid Chromatography Using a Novel Solid-phase Extraction Method in Patients Treated for Chronic Hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 802-806. | 2.0 | 28 |
| 303 | Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. <i>HIV Medicine</i> , 2009, 10, 53-59. | 2.2 | 28 |
| 304 | A Rapid Non-Culture-Based Assay for Clinical Monitoring of Phenotypic Resistance of Human Immunodeficiency Virus Type 1 to Lamivudine (3TC). <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 264-270. | 3.2 | 28 |
| 305 | LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. <i>Virus Research</i> , 1998, 57, 11-20. | 2.2 | 27 |
| 306 | Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. <i>Journal of Medical Virology</i> , 2005, 76, 268-270. | 5.0 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Impact of IL28B gene polymorphisms on interferon- α 3 plasma levels during pegylated interferon- α /ribavirin therapy for chronic hepatitis C in patients coinfectd with HIV. Journal of Antimicrobial Chemotherapy, 2012, 67, 1246-1249. | 3.0 | 27 |
| 308 | Genetic Determinants of Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients. Clinical Infectious Diseases, 2013, 56, 1117-1122. | 5.8 | 27 |
| 309 | Hepatitis B, C, and D and HIV Infections among Immigrants from Equatorial Guinea Living in Spain. American Journal of Tropical Medicine and Hygiene, 2013, 88, 789-794. | 1.4 | 27 |
| 310 | Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. Journal of Antimicrobial Chemotherapy, 2017, 72, 2083-2088. | 3.0 | 27 |
| 311 | Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. Clinical and Diagnostic Virology, 1996, 7, 85-92. | 1.7 | 26 |
| 312 | Performance of Six Different Ritonavir-Boosted Protease Inhibitor-Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients. HIV Clinical Trials, 2006, 7, 163-171. | 2.0 | 26 |
| 313 | Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis B Extensively Exposed to Antiretroviral Therapy with Anti-HBV Activity. HIV Clinical Trials, 2006, 7, 246-250. | 2.0 | 26 |
| 314 | Value of the HLA-B*5701 Allele to Predict Abacavir Hypersensitivity in Spaniards. AIDS Research and Human Retroviruses, 2007, 23, 1374-1376. | 1.1 | 26 |
| 315 | Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4+ and CD8+ T-cell responses to hepatitis C virus. Journal of Medical Virology, 2007, 79, 503-510. | 5.0 | 26 |
| 316 | Elite Controllers Display Higher Activation on Central Memory CD8 T Cells Than HIV Patients Successfully on HAART. AIDS Research and Human Retroviruses, 2011, 27, 157-165. | 1.1 | 26 |
| 317 | Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. Aids, 2011, 25, 269-271. | 2.2 | 26 |
| 318 | Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. Aids, 2011, 25, 761-766. | 2.2 | 26 |
| 319 | Advances in hepatitis B therapeutics. Therapeutic Advances in Infectious Disease, 2020, 7, 204993612096502. | 1.8 | 26 |
| 320 | Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. Aids, 1999, 13, 524. | 2.2 | 26 |
| 321 | Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. Aids, 2002, 16, 1830-1832. | 2.2 | 26 |
| 322 | Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. Journal of Infection, 1994, 28, 255-259. | 3.3 | 25 |
| 323 | Naturally Occurring Sequence Polymorphisms within HIV Type 1 Group O Protease. AIDS Research and Human Retroviruses, 2001, 17, 1555-1561. | 1.1 | 25 |
| 324 | Hcv Chronic Hepatitis in Patients With Hiv: Clinical Management Issues. American Journal of Gastroenterology, 2002, 97, 1598-1606. | 0.4 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α -2b Plus Ribavirin. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1083-1089. | 1.1 | 25 |
| 326 | Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. <i>Journal of Virological Methods</i> , 2004, 121, 115-118. | 2.1 | 25 |
| 327 | Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1171-1181. | 4.1 | 25 |
| 328 | Development of Tropical Spastic Paraparesis in Human T-Lymphotropic Virus Type 1 Carriers Is Influenced by Interleukin 28B Gene Polymorphisms. <i>Clinical Infectious Diseases</i> , 2012, 55, e1-e4. | 5.8 | 25 |
| 329 | Management and Treatment of Chronic Hepatitis C in HIV Patients. <i>Seminars in Liver Disease</i> , 2012, 32, 138-146. | 3.6 | 25 |
| 330 | Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283. | 2.5 | 25 |
| 331 | Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. <i>Aids</i> , 1999, 13, 525. | 2.2 | 25 |
| 332 | Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?. <i>Aids</i> , 2000, 14, 1672-1673. | 2.2 | 25 |
| 333 | Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. <i>Aids</i> , 2007, 21, 583-588. | 2.2 | 24 |
| 334 | Quantitative Detection of Plasma Human Immunodeficiency Virus Type 2 Subtype A RNA by the Nuclisens EasyQ Assay (Version 1.1). <i>Journal of Clinical Microbiology</i> , 2007, 45, 88-92. | 3.9 | 24 |
| 335 | Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 405-410. | 3.0 | 24 |
| 336 | Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. <i>Journal of Clinical Virology</i> , 2007, 38, 176-180. | 3.1 | 24 |
| 337 | Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2008, 15, 363-369. | 2.0 | 24 |
| 338 | HTLV infection among foreign pregnant women living in Spain. <i>Journal of Clinical Virology</i> , 2011, 52, 119-122. | 3.1 | 24 |
| 339 | Hepatitis B in HIV-Infected Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 489-501. | 2.1 | 24 |
| 340 | The changing face of hepatitis C in the new era of direct-acting antivirals. <i>Antiviral Research</i> , 2013, 97, 36-40. | 4.1 | 24 |
| 341 | Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. <i>Aids</i> , 2013, 27, 1129-1134. | 2.2 | 24 |
| 342 | IFNL4 rs469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , 2014, 9, e95515. | 2.5 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. <i>Aids</i> , 2014, 28, 1473-1478. | 2.2 | 24 |
| 344 | Towards hepatitis C eradication from the HIV-infected population. <i>Antiviral Research</i> , 2014, 105, 1-7. | 4.1 | 24 |
| 345 | Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 309-315. | 3.8 | 24 |
| 346 | Emerging viral infections—a potential threat for blood supply in the 21st century. <i>AIDS Reviews</i> , 2012, 14, 279-89. | 1.0 | 24 |
| 347 | Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. <i>HIV Clinical Trials</i> , 2002, 3, 99-114. | 2.0 | 23 |
| 348 | Characteristics and Prospects for Hepatitis C Therapy of an HIV-HCV Coinfected Population Followed at a Reference HIV Center. <i>HIV Clinical Trials</i> , 2005, 6, 329-336. | 2.0 | 23 |
| 349 | Heterogeneous nature of HIV-1 recombinants spreading in Spain. <i>Journal of Medical Virology</i> , 2005, 75, 374-380. | 5.0 | 23 |
| 350 | Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 23-28. | 5.0 | 23 |
| 351 | Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. <i>Aids</i> , 2006, 20, 1460-1462. | 2.2 | 23 |
| 352 | Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1647-1649. | 3.2 | 23 |
| 353 | Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3729-3742. | 3.2 | 23 |
| 354 | Antiretroviral drug-related toxicities — clinical spectrum, prevention, and management. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 697-707. | 2.4 | 23 |
| 355 | Emerging Challenges in Managing Hepatitis B in HIV Patients. <i>Current HIV/AIDS Reports</i> , 2015, 12, 344-352. | 3.1 | 23 |
| 356 | Treatment of hepatitis C with new fixed dose combinations. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1235-1242. | 1.8 | 23 |
| 357 | Chemokine receptors and HIV-2. <i>Aids</i> , 1997, 11, 1198-1199. | 2.2 | 22 |
| 358 | Treatment of chronic hepatitis C in HIV-positive individuals: Selection of candidates. <i>Journal of Hepatology</i> , 2006, 44, S44-S48. | 3.7 | 22 |
| 359 | Reliability of Rapid Subtyping Tools Compared to That of Phylogenetic Analysis for Characterization of Human Immunodeficiency Virus Type 1 Non-B Subtypes and Recombinant Forms. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3896-3899. | 3.9 | 22 |
| 360 | Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV— hepatitis C virus coinfecting patients. <i>Aids</i> , 2013, 27, 1187-1188. | 2.2 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062. | 3.0 | 22 |
| 362 | New hepatitis C therapies for special patient populations. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 217-229. | 1.8 | 22 |
| 363 | MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression. <i>PLoS ONE</i> , 2016, 11, e0155245. | 2.5 | 22 |
| 364 | Seroreversion in Patients with End-stage HIV Infection. <i>Vox Sanguinis</i> , 1994, 67, 238-239. | 1.5 | 21 |
| 365 | Sequence Note:envGene Characterization of the First HIV Type 1 Group O Spanish Isolate. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1647-1649. | 1.1 | 21 |
| 366 | Molecular Evidence of Homosexual Transmission of HIV Type 2 in Spain. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 417-422. | 1.1 | 21 |
| 367 | Avascular Necrosis in HIV-Infected Patients Receiving Antiretroviral Treatment: Study of Seven Cases. <i>HIV Clinical Trials</i> , 2003, 4, 132-136. | 2.0 | 21 |
| 368 | Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 460-464. | 5.0 | 21 |
| 369 | Prevalence of HIV infection among young adult injecting and non-injecting heroin users in Spain in the era of harm reduction programmes: gender differences and other related factors. <i>Epidemiology and Infection</i> , 2007, 135, 592-603. | 2.1 | 21 |
| 370 | Elevated TGF- β 1 levels might protect HCV/HIV-1 coinfected patients from liver fibrosis. <i>European Journal of Clinical Investigation</i> , 2011, 41, 70-76. | 3.4 | 21 |
| 371 | Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1. <i>Journal of Neurology</i> , 2013, 260, 2551-2555. | 3.6 | 21 |
| 372 | Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. <i>International Journal of Infectious Diseases</i> , 2021, 112, 81-88. | 3.3 | 21 |
| 373 | The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. <i>Journal of Infection</i> , 1998, 36, 307-311. | 3.3 | 20 |
| 374 | Regression of Invasive AIDS-Related Kaposi's Sarcoma Following Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 1998, 26, 218-219. | 5.8 | 20 |
| 375 | Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. <i>Aids</i> , 2000, 14, 913-919. | 2.2 | 20 |
| 376 | Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. <i>Sexually Transmitted Infections</i> , 2002, 78, 255-260. | 1.9 | 20 |
| 377 | CD4+T Cell Recovery beyond the First Year of Complete Suppression of Viral Replication during Highly Active Antiretroviral Therapy Is Not Influenced by CD8+T Cell Activation. <i>Journal of Infectious Diseases</i> , 2005, 192, 2142-2146. | 4.0 | 20 |
| 378 | Successful rescue therapy with darunavir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. <i>Aids</i> , 2006, 20, 1558-1560. | 2.2 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 379 | Liver Fibrosis Stage and HCV Genotype Distribution in HIV+HCV Coinfected Patients with Persistently Normal Transaminases. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 801-804. | 1.1 | 20 |
| 380 | Outbreak of Syphilis, but Not of Acute Hepatitis C, Among HIV-Infected Homosexual Men in Madrid. <i>HIV Clinical Trials</i> , 2007, 8, 98-101. | 2.0 | 20 |
| 381 | Introduction of Non-B Subtypes among Spaniards Newly Diagnosed with HIV Type 1 in the Canary Islands. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 498-502. | 1.1 | 20 |
| 382 | Hepatitis C Virus Coinfection Does Not Affect CD4 Restoration in HIV-Infected Patients after Initiation of Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 935-940. | 1.1 | 20 |
| 383 | Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV+hepatitis C virus-coinfected patients with prior nonresponse or relapse. <i>Aids</i> , 2011, 25, 1131-1133. | 2.2 | 20 |
| 384 | Hepatitis C Therapy: Highlights From the 2012 Annual Meeting of the European Association for the Study of the Liver. <i>Clinical Infectious Diseases</i> , 2013, 56, 560-566. | 5.8 | 20 |
| 385 | Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfecting patients. <i>Journal of Translational Medicine</i> , 2016, 14, 257. | 4.4 | 20 |
| 386 | Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1060-1062. | 1.6 | 20 |
| 387 | HTLV-1 infection in solid organ transplant donors and recipients in Spain. <i>BMC Infectious Diseases</i> , 2019, 19, 706. | 2.9 | 20 |
| 388 | Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz070. | 0.9 | 20 |
| 389 | Hospital admissions in individuals with HTLV-1 infection in Spain. <i>Aids</i> , 2020, 34, 1019-1027. | 2.2 | 20 |
| 390 | The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518. | 4.1 | 20 |
| 391 | Short Communication:Prevalence of G333D/E in Naive and Pretreated HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 857-860. | 1.1 | 19 |
| 392 | Viral Response to Antiretroviral Therapy in a Patient Coinfected with HIV Type 1 and Type 2. <i>Clinical Infectious Diseases</i> , 2005, 41, e19-e21. | 5.8 | 19 |
| 393 | Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 839-850. | 1.8 | 19 |
| 394 | Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1782-1785. | 5.8 | 19 |
| 395 | Injecting, Sexual Risk Behaviors and HIV Infection in Young Cocaine and Heroin Users in Spain. <i>European Addiction Research</i> , 2009, 15, 171-178. | 2.4 | 19 |
| 396 | European guideline for the management of hepatitis B and C virus infections, 2010. <i>International Journal of STD and AIDS</i> , 2010, 21, 669-678. | 1.1 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 397 | Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2502-2504. | 3.0 | 19 |
| 398 | Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. <i>Journal of Infection</i> , 2011, 63, 382-390. | 3.3 | 19 |
| 399 | Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2838-2842. | 3.0 | 19 |
| 400 | A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752. | 4.0 | 19 |
| 401 | Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2013, 27, 2001. | 2.2 | 19 |
| 402 | Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004-2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. <i>PLoS ONE</i> , 2014, 9, e116226. | 2.5 | 19 |
| 403 | Emerging antiretroviral drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 211-219. | 1.8 | 19 |
| 404 | IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. <i>Aids</i> , 2015, 29, 1895-1897. | 2.2 | 19 |
| 405 | Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group. <i>Journal of Clinical Microbiology</i> , 1995, 33, 1735-1738. | 3.9 | 19 |
| 406 | False positives for HIV using commercial viral load quantification assays. <i>Aids</i> , 1998, 12, 2076-2077. | 2.2 | 18 |
| 407 | Human immunodeficiency viruses type 1 subtypes circulating in Spain. <i>Journal of Medical Virology</i> , 1999, 59, 189-193. | 5.0 | 18 |
| 408 | Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. <i>HIV Clinical Trials</i> , 2002, 3, 9-16. | 2.0 | 18 |
| 409 | Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 41, 154-159. | 2.1 | 18 |
| 410 | Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 626-627. | 3.0 | 18 |
| 411 | HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. <i>Antiviral Therapy</i> , 2011, 16, 585-589. | 1.0 | 18 |
| 412 | High Concordance between the Position-Specific Scoring Matrix and Geno2pheno Algorithms for Genotypic Interpretation of HIV-1 Tropism: V3 Length as the Major Cause of Disagreement. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3380-3382. | 3.9 | 18 |
| 413 | Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 156-164. | 1.1 | 18 |
| 414 | Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1517-1527. | 3.9 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | Hepatic Decompensation with Sofosbuvir plus Simeprevir in a Patient with Childâ€Pugh B Compensated Cirrhosis. <i>Antiviral Therapy</i> , 2016, 21, 91-92. | 1.0 | 18 |
| 416 | Interferonâ€free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: <scp>SOUND</scp>â€C3, a Phase 2b study. <i>Liver International</i> , 2015, 35, 417-421. | 3.9 | 18 |
| 417 | HIV type 2 epidemic in Spain. <i>Aids</i> , 2017, 31, 1353-1364. | 2.2 | 18 |
| 418 | Replacing stavudine by abacavir reduces lactate levels and may improve lipotrophy. <i>Aids</i> , 2003, 17, 921-924. | 2.2 | 18 |
| 419 | Report from the International Conference on Viral Hepatitis (ICVH) â€“ Chicago, October 2017. <i>AIDS Reviews</i> , 2018, 20, . | 1.0 | 18 |
| 420 | High morbidity and mortality of chronic viral liver disease in HIV-infected individuals in Spain. <i>Journal of Infection</i> , 1994, 28, 100-102. | 3.3 | 17 |
| 421 | Human Immunodeficiency Virus Type 2 Infection in Spain. <i>Intervirolgy</i> , 1999, 42, 37-42. | 2.8 | 17 |
| 422 | Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. <i>Journal of Medical Virology</i> , 2001, 63, 85-87. | 5.0 | 17 |
| 423 | Human T Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis in an HIV-Positive Patient Coinfected with Human T Lymphotropic Virus Type 2 Following Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2007, 45, e118-e120. | 5.8 | 17 |
| 424 | Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. <i>Virus Genes</i> , 2007, 34, 111-116. | 1.6 | 17 |
| 425 | Genetic characterization of complex interâ€recombinant HIVâ€1 strains circulating in Spain and reliability of distinct rapid subtyping tools. <i>Journal of Medical Virology</i> , 2008, 80, 383-391. | 5.0 | 17 |
| 426 | Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1470-1472. | 3.0 | 17 |
| 427 | Editorial Commentary:Risks and Benefits of Using Antiretroviral Therapy in HIVâ€infected Patients with Chronic Hepatitis B in Developing Regions. <i>Clinical Infectious Diseases</i> , 2008, 47, 1486-1489. | 5.8 | 17 |
| 428 | Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 333-340. | 1.0 | 17 |
| 429 | Short Communication High Risk of Endothelial Dysfunction in HIV Individuals May Result from Deregulation of Circulating Endothelial Cells and Endothelial Progenitor Cells. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 656-659. | 1.1 | 17 |
| 430 | <i><scp>IL</scp>28<scp>RA</scp></i> polymorphism is associated with early hepatitis <scp>C</scp> virus (<scp>HCV</scp>) treatment failure in human immunodeficiency virusâ€<scp>HCV</scp>â€coinfected patients. <i>Journal of Viral Hepatitis</i> , 2013, 20, 358-366. | 2.0 | 17 |
| 431 | Faldaprevir and pegylated interferon Î±-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. <i>Aids</i> , 2015, 29, 571-581. | 2.2 | 17 |
| 432 | Dual antiviral therapy for HIV and hepatitis C â€“ drug interactions and side effects. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1421-1434. | 2.4 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 433 | CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878. | 3.0 | 17 |
| 434 | Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. <i>Clinical Microbiology and Infection</i> , 2001, 7, 678-681. | 6.0 | 16 |
| 435 | HIV-Positive Immigrants in the Canary Islands, Spain: Implications for Public Health in Europe. <i>HIV Clinical Trials</i> , 2003, 4, 184-192. | 2.0 | 16 |
| 436 | Hydroxyurea plus Didanosine as Maintenance Therapy for HIV-Infected Patients on Long-Term Successful Highly Active Antiretroviral Therapy. <i>HIV Clinical Trials</i> , 2003, 4, 361-371. | 2.0 | 16 |
| 437 | Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. <i>Aids</i> , 2004, 18, 2091-2094. | 2.2 | 16 |
| 438 | Influence of Human T Cell Lymphotropic Virus Type 2 Coinfection on Virological and Immunological Parameters in HIV Type 1-Infected Patients. <i>Clinical Infectious Diseases</i> , 2007, 44, 105-110. | 5.8 | 16 |
| 439 | Impact of Ethnicity and HIV Type 1 Subtype on Response to First-Line Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 891-894. | 1.1 | 16 |
| 440 | Prevalence of and Risk Factors for Hepatitis B Virus Infection among Street-Recruited Young Injection and Non-Injection Heroin Users in Barcelona, Madrid and Seville. <i>European Addiction Research</i> , 2008, 14, 116-124. | 2.4 | 16 |
| 441 | Clinical Differences and Viral Diversity between Newly HIV Type 1-Diagnosed African and Non-African Patients in Spain (2005-2007). <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 37-44. | 1.1 | 16 |
| 442 | Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675. | 1.0 | 16 |
| 443 | Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. <i>HIV Medicine</i> , 2011, 12, 487-493. | 2.2 | 16 |
| 444 | Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2011, 53, 1291-1295. | 5.8 | 16 |
| 445 | Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. <i>European Journal of Immunology</i> , 2013, 43, 499-509. | 2.9 | 16 |
| 446 | Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. <i>HIV Medicine</i> , 2013, 14, 370-378. | 2.2 | 16 |
| 447 | Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 475-479. | 2.0 | 16 |
| 448 | Liver Fibrosis Progression despite HCV Cure with Antiviral Therapy in HIV-HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2015, 20, 329-334. | 1.0 | 16 |
| 449 | Long-term survival and liver-related events after peginterferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2014, 20, 65-72. | 1.0 | 16 |
| 450 | Hypoglycemia in a diabetic patient during hepatitis C therapy. <i>Hepatology</i> , 2016, 63, 2065-2066. | 7.3 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 451 | Decline and Changing Profile of Hepatitis Delta among Injection Drug users in Spain. <i>Antiviral Therapy</i> , 2018, 23, 87-90. | 1.0 | 16 |
| 452 | Drug interactions in HIV-infected patients treated for hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 807-816. | 3.3 | 16 |
| 453 | Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1357-1362. | 3.0 | 16 |
| 454 | Long-acting antiretroviral therapy. <i>Nature Materials</i> , 2020, 19, 826-827. | 27.5 | 16 |
| 455 | Why such excess of mortality for COVID-19 in Spain?. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612093275. | 1.8 | 16 |
| 456 | High rate of co-infection with different hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain. <i>Journal of Hepatology</i> , 1995, 22, 598-599. | 3.7 | 15 |
| 457 | A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. <i>Journal of Infection</i> , 1997, 35, 225-230. | 3.3 | 15 |
| 458 | New paradigms in the management of HIV and hepatitis C virus coinfection. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 550-560. | 3.1 | 15 |
| 459 | Hepatic and Renal Safety Profile of Tenofovir in HIV-Infected Patients with Hepatitis C, Including Patients on Interferon Plus Ribavirin. <i>HIV Clinical Trials</i> , 2005, 6, 278-280. | 2.0 | 15 |
| 460 | Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain. <i>Journal of Clinical Virology</i> , 2005, 33, 65-70. | 3.1 | 15 |
| 461 | Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. <i>Clinical and Translational Oncology</i> , 2006, 8, 193-199. | 2.4 | 15 |
| 462 | Limited but increasing use of treatment for hepatitis C across Europe in patients coinfecting with HIV and hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 1092-1097. | 1.5 | 15 |
| 463 | Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2007, 14, 392-395. | 2.0 | 15 |
| 464 | Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. <i>Journal of Viral Hepatitis</i> , 2008, 15, 710-715. | 2.0 | 15 |
| 465 | Prevalence of HTLV-1/2 Infections in Spain: A Cross-Sectional Hospital-Based Survey. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 861-864. | 1.1 | 15 |
| 466 | Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 641-644. | 3.0 | 15 |
| 467 | Strategic use of lamivudine in the management of chronic hepatitis B. <i>Antiviral Research</i> , 2013, 100, 435-438. | 4.1 | 15 |
| 468 | HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. <i>Aids</i> , 2013, 27, 1231-1238. | 2.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 469 | Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. <i>Aids</i> , 2013, 27, 2219-2224. | 2.2 | 15 |
| 470 | HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. <i>Aids</i> , 2013, 27, 1375-1385. | 2.2 | 15 |
| 471 | Pharmacokinetics of new oral hepatitis C antiviral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 5-16. | 3.3 | 15 |
| 472 | Characterization of Free Phenytoin Concentrations in End-Stage Renal Disease Using the Winter-Tozer Equation. <i>Annals of Pharmacotherapy</i> , 2017, 51, 669-674. | 1.9 | 15 |
| 473 | Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS. <i>AIDS Reviews</i> , 2019, 20, 187-204. | 1.0 | 15 |
| 474 | Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain. <i>Clinical Infectious Diseases</i> , 2021, 72, 1101-1102. | 5.8 | 15 |
| 475 | Spanish consensus conference on drug resistance testing in clinical practice. <i>Aids</i> , 1999, 13, 1998. | 2.2 | 15 |
| 476 | Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. <i>Aids</i> , 2002, 16, 493-495. | 2.2 | 15 |
| 477 | Genetic mechanisms of resistance to NRTI and NNRTI. <i>HIV Clinical Trials</i> , 2002, 3, 237-48. | 2.0 | 15 |
| 478 | Enhanced diagnostic efficiency of the polymerase chain reaction by co-amplification of multiple regions of HIV-1 and HIV-2. <i>Journal of Virological Methods</i> , 1994, 49, 37-46. | 2.1 | 14 |
| 479 | Rate, Causes, and Clinical Implications of Presenting with Low CD4+ Cell Counts in the Era of Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 363-368. | 1.1 | 14 |
| 480 | Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8 ⁺ T cells. <i>European Journal of Immunology</i> , 2008, 38, 1548-1558. | 2.9 | 14 |
| 481 | Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 967-972. | 1.1 | 14 |
| 482 | Changing Rate of Non-B Subtypes and Coinfection with Hepatitis B/C Viruses in Newly Diagnosed HIV Type 1 Individuals in Spain. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 633-638. | 1.1 | 14 |
| 483 | Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1007-1014. | 1.8 | 14 |
| 484 | Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 517-530. | 2.4 | 14 |
| 485 | Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2616-2625. | 3.0 | 14 |
| 486 | X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. <i>Aids</i> , 2014, 28, 1603-1609. | 2.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 487 | HIV co-infection in HTLV-1 carriers in Spain. <i>Virus Research</i> , 2019, 266, 48-51. | 2.2 | 14 |
| 488 | Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. <i>Journal of Infectious Diseases</i> , 2020, 221, 1962-1972. | 4.0 | 14 |
| 489 | Sequencing antiretroviral drugs. <i>Aids</i> , 2001, 15, 547-551. | 2.2 | 13 |
| 490 | Indinavir Plasma Concentrations and Resistance Mutations in Patients Experiencing Early Virological Failure. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 457-459. | 1.1 | 13 |
| 491 | Management of Chronic Hepatitis C in Patients Co-Infected with HIV. <i>Drug Safety</i> , 2004, 27, 7-24. | 3.2 | 13 |
| 492 | Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. <i>Journal of Viral Hepatitis</i> , 2006, 13, 851-857. | 2.0 | 13 |
| 493 | Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1237-1241. | 1.1 | 13 |
| 494 | Amino Acid Conservation in the gp41 Transmembrane Protein and Natural Polymorphisms Associated with Enfuvirtide Resistance across HIV-1 Variants. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1067-1074. | 1.1 | 13 |
| 495 | Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy "ask, draw a blood sample, vaccinate and try to schedule another visit". <i>Journal of Clinical Virology</i> , 2007, 38, 87-90. | 3.1 | 13 |
| 496 | Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients. <i>HIV Clinical Trials</i> , 2008, 9, 440-444. | 2.0 | 13 |
| 497 | No Major Differences in the Functional Profile of HIV Gag and Nef-Specific CD8 ⁺ Responses between Long-Term Nonprogressors and Typical Progressors. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1185-1195. | 1.1 | 13 |
| 498 | Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. <i>Aids</i> , 2010, 24, 469-471. | 2.2 | 13 |
| 499 | Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. <i>Antiviral Therapy</i> , 2011, 17, 571-575. | 1.0 | 13 |
| 500 | Short Communication: Does Interleukin-28B Single Nucleotide Polymorphisms Influence the Natural History of Hepatitis B?. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1262-1264. | 1.1 | 13 |
| 501 | Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1015-1022. | 3.3 | 13 |
| 502 | Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges. <i>Cancer</i> , 2018, 124, 1647-1649. | 4.1 | 13 |
| 503 | Epidemiology of human T-lymphotropic virus type II (HTLV-II) infection in Spain. <i>European Journal of Epidemiology</i> , 1996, 12, 625-629. | 5.7 | 12 |
| 504 | Primary lymphoma of the central nervous system and HTLV-I infection. <i>Haematologia</i> , 2001, 31, 365-367. | 0.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 505 | A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. <i>HIV Medicine</i> , 2002, 3, 229-238. | 2.2 | 12 |
| 506 | Performance of drug resistance assays in testing HIV-1 non-B subtypes. <i>Clinical Microbiology and Infection</i> , 2003, 9, 323-326. | 6.0 | 12 |
| 507 | Human immunodeficiency virus type 1 recombinant B/G subtypes circulating in Coimbra, Portugal. <i>Clinical Microbiology and Infection</i> , 2003, 9, 422-425. | 6.0 | 12 |
| 508 | Gynecomastia in HIV-Infected Patients Receiving Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 739-741. | 1.1 | 12 |
| 509 | Risks and benefits of antiretroviral therapy in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2005, 42, 290-292. | 3.7 | 12 |
| 510 | Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation. <i>Clinical and Experimental Immunology</i> , 2007, 149, 171-177. | 2.6 | 12 |
| 511 | Hepatitis B vaccination: An unmet challenge in the era of harm reduction programs. <i>Journal of Substance Abuse Treatment</i> , 2008, 34, 398-406. | 2.8 | 12 |
| 512 | A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1. <i>Aids</i> , 2008, 22, 911-912. | 2.2 | 12 |
| 513 | A Highly Sensitive and Specific Model for Predicting HIV-1 Tropism in Treatment-Experienced Patients Combining Interpretation of V3 Loop Sequences and Clinical Parameters. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 51-58. | 2.1 | 12 |
| 514 | Different impact of IL28B polymorphisms on response to peginterferon- α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. <i>Journal of Clinical Virology</i> , 2012, 55, 58-61. | 3.1 | 12 |
| 515 | Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 163-173. | 2.2 | 12 |
| 516 | Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715. | 1.0 | 12 |
| 517 | Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. <i>Clinical Microbiology and Infection</i> , 2015, 21, 1027-1032. | 6.0 | 12 |
| 518 | Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2015, 71, 63-66. | 3.1 | 12 |
| 519 | Occult hepatitis B and HIV infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1403-1407. | 1.6 | 12 |
| 520 | Hepatitis B in HIV patients: what is the current treatment and what are the challenges?. <i>Journal of HIV Therapy</i> , 2009, 14, 13-8. | 0.6 | 12 |
| 521 | Diabetes Mellitus Associated with Protease Inhibitor Use. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 675-677. | 2.9 | 11 |
| 522 | Phylogeny of HIV Type 1 Group O Isolates Based on env Gene Sequences. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 769-773. | 1.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 523 | Role of Baseline Human Immunodeficiency Virus Genotype as a Predictor of Viral Response to Tenofovir in Heavily Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4421-4423. | 3.9 | 11 |
| 524 | Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. <i>Aids</i> , 2004, 18, 1251-1261. | 2.2 | 11 |
| 525 | Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption. <i>Clinical Infectious Diseases</i> , 2005, 41, 897-900. | 5.8 | 11 |
| 526 | Escape Mutations in HIV Infection and its Impact on CD8+ T Cell Responses. <i>Current Molecular Medicine</i> , 2007, 7, 446-458. | 1.3 | 11 |
| 527 | Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants. <i>Antiviral Research</i> , 2010, 88, 152-159. | 4.1 | 11 |
| 528 | New therapeutic strategies for raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 218-223. | 3.0 | 11 |
| 529 | Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. <i>Aids</i> , 2010, 24, 777-779. | 2.2 | 11 |
| 530 | New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. <i>Aids</i> , 2011, 25, 1013-1014. | 2.2 | 11 |
| 531 | Short Communication: Use of Serum Bilirubin Levels as Surrogate Marker of Early Virological Response to Atazanavir-Based Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1043-1045. | 1.1 | 11 |
| 532 | HIV gag-specific immune response mediated by double negative (CD3 ⁺ CD4 ⁺ CD8 ⁺) T cells in HIV-exposed seronegative individuals. <i>Journal of Medical Virology</i> , 2013, 85, 200-209. | 5.0 | 11 |
| 533 | Management and treatment of chronic hepatitis B in HIV-positive patients. <i>Annals of Medicine</i> , 2014, 46, 290-296. | 3.8 | 11 |
| 534 | Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 700-708. | 1.2 | 11 |
| 535 | Pharmacogenetics of antiretroviral therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1119-1130. | 3.3 | 11 |
| 536 | Changing utilization of Stavudine (d4T) in HIV-positive people in 2006–2013 in the EuroSIDA study. <i>HIV Medicine</i> , 2015, 16, 533-543. | 2.2 | 11 |
| 537 | HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012). <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2016, 58, 11. | 1.1 | 11 |
| 538 | Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx228. | 0.9 | 11 |
| 539 | Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. <i>International Journal of Infectious Diseases</i> , 2022, 114, 45-50. | 3.3 | 11 |
| 540 | Pyomyositis in patients with HIV infection. <i>Aids</i> , 1993, 7, 1020-1021. | 2.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 541 | Circulating Hepatitis C Virus Genotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 180-181. | 1.5 | 10 |
| 542 | Epidemiology of HTLV-I Infection in Spain. <i>International Journal of Epidemiology</i> , 1996, 25, 443-449. | 1.9 | 10 |
| 543 | Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections. <i>Transfusion Science</i> , 1997, 18, 63-69. | 0.6 | 10 |
| 544 | CCR5 genotype and HIV-1 infection in perinatally-exposed infants. <i>Journal of Infection</i> , 1999, 38, 9-11. | 3.3 | 10 |
| 545 | Prevalence and Genetic Heterogeneity of the Reverse Transcriptase T69S-S-X Insertion in Pretreated HIV-Infected Patients. <i>Intervirology</i> , 2001, 44, 339-343. | 2.8 | 10 |
| 546 | Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays. <i>Journal of Medical Virology</i> , 2001, 64, 217-222. | 5.0 | 10 |
| 547 | HIV-1 Subtype J Recombinant Viruses in Spain. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 523-529. | 1.1 | 10 |
| 548 | Infection with Retroviruses Other Than HIV-1 in Spain: A Retrospective Analysis for HIV-2, HTLV-I, and/or HTLV-II. <i>HIV Clinical Trials</i> , 2002, 3, 397-402. | 2.0 | 10 |
| 549 | Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. <i>Aids</i> , 2006, 20, 451-453. | 2.2 | 10 |
| 550 | Drug Interactions of Tipranavir, a New HIV Protease Inhibitor. <i>Drug Metabolism Letters</i> , 2007, 1, 81-84. | 0.8 | 10 |
| 551 | Low Rate of Adverse Hepatic Events Associated with Fosamprenavir/Ritonavir-Based Antiretroviral Regimens. <i>HIV Clinical Trials</i> , 2008, 9, 309-313. | 2.0 | 10 |
| 552 | New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 379-382. | 3.0 | 10 |
| 553 | Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64. | 3.3 | 10 |
| 554 | Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. <i>Journal of Clinical Virology</i> , 2013, 58, 391-395. | 3.1 | 10 |
| 555 | Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. <i>Aids</i> , 2013, 27, 687-696. | 2.2 | 10 |
| 556 | Very Late Relapse after Discontinuation of Antiviral Therapy for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 1033-1035. | 1.0 | 10 |
| 557 | Dolutegravir, abacavir and lamivudine as HIV therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1051-1057. | 1.8 | 10 |
| 558 | Molecular Epidemiology and Clinical Features of Human T Cell Lymphotropic Virus Type 1 Infection in Spain. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 856-862. | 1.1 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 559 | Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1282-1291. | 3.2 | 10 |
| 560 | Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions. <i>AIDS Reviews</i> , 2021, 22, 44-56. | 1.0 | 10 |
| 561 | Update on the treatment of chronic hepatitis C in HIV-infected patients. <i>AIDS Reviews</i> , 2007, 9, 99-113. | 1.0 | 10 |
| 562 | Misdiagnosis of HTLV-II infection using HTLV-I screening assays. <i>Aids</i> , 1993, 7, 1395. | 2.2 | 9 |
| 563 | Significance of HCV RIBA Indeterminate Results in High-Risk Individuals: Assessment by a New Third-Generation RIBA Assay and PCR. <i>Vox Sanguinis</i> , 1994, 66, 148-149. | 1.5 | 9 |
| 564 | Evidence of HIV-2 Infection in Equatorial Guinea (Central Africa): Partial Genetic Analysis of a B Subtype Virus. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 439-440. | 1.1 | 9 |
| 565 | Tropism, Coreceptor Use, and Phylogenetic Analysis of Both the V3 Loop and the Protease Gene of Three Novel HIV-1 Group O Isolates. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 417-425. | 0.3 | 9 |
| 566 | Does an Increase in Nevirapine Plasma Levels Cause Complete Virologic Suppression in Patients Experiencing Early Virologic Failure?. <i>HIV Clinical Trials</i> , 2002, 3, 463-467. | 2.0 | 9 |
| 567 | Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. <i>HIV Clinical Trials</i> , 2002, 3, 249-257. | 2.0 | 9 |
| 568 | New Hopes for HIV and HCV Coinfection in 2004. <i>HIV Clinical Trials</i> , 2004, 5, 232-251. | 2.0 | 9 |
| 569 | Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group. <i>Haemophilia</i> , 2005, 11, 433-437. | 2.1 | 9 |
| 570 | Variability in the P6gag domains of HIV-1 involved in viral budding. <i>Aids</i> , 2006, 20, 624-627. | 2.2 | 9 |
| 571 | Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1411-1413. | 3.0 | 9 |
| 572 | Management of hepatitis B virus co-infection on and off antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , 2008, 5, 86-93. | 3.1 | 9 |
| 573 | Liver Complications Have Reached a Plateau as Cause of Hospital Admission and Death in HIV Patients in Madrid. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 383-385. | 1.1 | 9 |
| 574 | Short Communication: Severe Immune Suppression in Patients Infected with R5-Tropic HIV-1 Strains Is Associated with Increased gp120 Net Charge at Variable Regions. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 965-967. | 1.1 | 9 |
| 575 | Drug resistance testing in hepatitis C therapy. <i>Future Virology</i> , 2012, 7, 309-321. | 1.8 | 9 |
| 576 | Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. <i>Aids</i> , 2012, 26, 551-557. | 2.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 577 | Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1994-2002. | 3.0 | 9 |
| 578 | A polymorphism linked to <i>RRAS</i> , <i>SCAF1</i> , <i>IRF3</i> and <i>BCL2L12</i> genes is associated with cirrhosis in hepatitis C virus carriers. <i>Liver International</i> , 2014, 34, 558-566. | 3.9 | 9 |
| 579 | Progression to advanced liver fibrosis in HIV/HCV-coinfected patients and prioritization of new hepatitis C therapies. <i>Antiviral Therapy</i> , 2014, 19, 799-803. | 1.0 | 9 |
| 580 | AIDS Clinical Research in Spain—Large HIV Population, Geniality of Doctors, and Missing Opportunities. <i>Viruses</i> , 2018, 10, 293. | 3.3 | 9 |
| 581 | Multiple recombinant events in human T-cell Leukemia virus Type 1: complete sequences of recombinant African strains. <i>Emerging Microbes and Infections</i> , 2020, 9, 913-923. | 6.5 | 9 |
| 582 | Coronavirus and other airborne agents with pandemic potential. <i>Current Opinion in Environmental Science and Health</i> , 2020, 17, 41-48. | 4.1 | 9 |
| 583 | What dual protease inhibitor combination for salvage therapies?. <i>Aids</i> , 1999, 13, 2180. | 2.2 | 9 |
| 584 | Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy. <i>Aids</i> , 2002, 16, 1087-1089. | 2.2 | 9 |
| 585 | The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain. <i>AIDS Reviews</i> , 2015, 17, 212-9. | 1.0 | 9 |
| 586 | Multifocal splenic abscesses caused by <i>Mycobacterium tuberculosis</i> in HIV-infected drug users. <i>Aids</i> , 1991, 5, 901. | 2.2 | 8 |
| 587 | Hepatitis C viraemia in HIV-infected patients. <i>Aids</i> , 1996, 10, 922. | 2.2 | 8 |
| 588 | Sequence Note: env Gene Diversity of HIV Type 1 Isolates from Spain. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 955-957. | 1.1 | 8 |
| 589 | Higher antiviral activity of antiretroviral regimens including protease inhibitors. <i>Aids</i> , 1999, 13, 998. | 2.2 | 8 |
| 590 | Relationship between drug resistance mutations, plasma viremia, and CD4+T-cell counts in patients with chronic HIV infection. <i>Journal of Medical Virology</i> , 2005, 76, 1-6. | 5.0 | 8 |
| 591 | Failure of Hepatitis C Therapy in HIV-Infected Drug Users Is Not Due to a Shift in Hepatitis C Virus Genotype. <i>Journal of Infectious Diseases</i> , 2005, 192, 1245-1248. | 4.0 | 8 |
| 592 | Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. <i>Aids</i> , 2005, 19, 621-623. | 2.2 | 8 |
| 593 | Short Communication: Dynamics of Drug-Resistant HIV-1 in Plasma and Peripheral Blood Cells in Patients during and after Enfuvirtide Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1078-1082. | 1.1 | 8 |
| 594 | Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. <i>Aids</i> , 2008, 22, 311-313. | 2.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 595 | Seroreversion of Hepatitis C Virus (HCV) Antibodies in an HIV-Infected Patient despite Continuous HCV Replication. <i>Clinical Infectious Diseases</i> , 2009, 48, 1634-1635. | 5.8 | 8 |
| 596 | Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3018-3020. | 3.2 | 8 |
| 597 | Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. <i>Journal of Medical Virology</i> , 2013, 85, 1734-1740. | 5.0 | 8 |
| 598 | ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 27-32. | 2.1 | 8 |
| 599 | Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. <i>HIV Clinical Trials</i> , 2015, 16, 72-80. | 2.0 | 8 |
| 600 | Gene therapy for HIV infection. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 319-327. | 3.1 | 8 |
| 601 | Tenofovir for Hepatitis Delta. <i>Hepatology</i> , 2016, 63, 1395-1396. | 7.3 | 8 |
| 602 | Hepatitis Delta Enters a New Therapeutic Era. <i>Journal of Infectious Diseases</i> , 2018, 217, 1173-1176. | 4.0 | 8 |
| 603 | Short article: Hepatitis delta in patients with resolved hepatitis B virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1063-1065. | 1.6 | 8 |
| 604 | HTLV testing of solid organ transplant donors. <i>Clinical Transplantation</i> , 2019, 33, e13670. | 1.6 | 8 |
| 605 | Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz036. | 0.9 | 8 |
| 606 | HTLV-1 infection and health outcomes. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 407-408. | 9.1 | 8 |
| 607 | New SARS-CoV-2 Variants Challenge Vaccines Protection. <i>AIDS Reviews</i> , 2021, 23, 57-58. | 1.0 | 8 |
| 608 | Envisioning a hepatitis delta cure with new antivirals. <i>Future Microbiology</i> , 2021, 16, 927-930. | 2.0 | 8 |
| 609 | Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2000, 14, 2409-2410. | 2.2 | 8 |
| 610 | HIV-2 and HTLV-1 infections in Spain, a non-endemic region. <i>AIDS Reviews</i> , 2014, 16, 152-9. | 1.0 | 8 |
| 611 | Hepatitis A Outbreaks in European Homosexual Men. <i>AIDS Reviews</i> , 2017, 19, 113-114. | 1.0 | 8 |
| 612 | Evaluation of a New Saliva Collection Device for HIV Antibody Screening Purposes. <i>Vox Sanguinis</i> , 1994, 66, 244-244. | 1.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 613 | Ion-pair reversed-phase and low-molecular-weight aqueous gel permeation high-performance liquid chromatography methods for the determination of amoxicillin oligomers. <i>Chromatographia</i> , 1995, 41, 651-656. | 1.3 | 7 |
| 614 | High Rate of Indeterminate Reactivity to HTLV in Western Blot Analysis of Spanish Blood Donors. <i>Vox Sanguinis</i> , 1996, 70, 120-121. | 1.5 | 7 |
| 615 | Sexual Transmission of Two Different HCV Types Causing Acute Hepatitis C. <i>Vox Sanguinis</i> , 1996, 71, 244-245. | 1.5 | 7 |
| 616 | SENV Infection in HIV-Positive Patients: Prevalence, Subtype Characterization, and Impact on HIV Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1079-1082. | 1.1 | 7 |
| 617 | Long-Term Outcome of HIV-Infected Patients with Multinucleoside-Resistant Genotypes. <i>HIV Clinical Trials</i> , 2003, 4, 372-381. | 2.0 | 7 |
| 618 | Hepatitis C Viremia in HIV/HCV-Coinfected Patients: Lower Levels in Presence of Chronic Hepatitis B. <i>HIV Clinical Trials</i> , 2005, 6, 103-106. | 2.0 | 7 |
| 619 | Can the Level of Immunosuppression in Human Immunodeficiency Virus-Infected Patients Affect the Reliability of Human T-Cell Lymphotropic Virus Type 2 Serological Diagnosis?. <i>Vaccine Journal</i> , 2006, 13, 160-161. | 3.1 | 7 |
| 620 | Short Communication: Hospital-Based Surveillance for HTLV-1/2 Infections in Spain. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1075-1077. | 1.1 | 7 |
| 621 | Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012, 9, 68. | 2.0 | 7 |
| 622 | Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 931-948. | 5.1 | 7 |
| 623 | Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013, 27, 2715-2724. | 2.2 | 7 |
| 624 | Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 179-186. | 1.8 | 7 |
| 625 | Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478. | 2.2 | 7 |
| 626 | Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppressors and failure of antiretrovirals. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611986802. | 1.8 | 7 |
| 627 | Screening for retroviruses and hepatitis viruses using dried blood spots reveals a high prevalence of occult hepatitis B in Ghana. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611985146. | 1.8 | 7 |
| 628 | Treatment outcome in dually HIV-1 and HIV-2 coinfecting patients living in Spain. <i>Aids</i> , 2019, 33, 2167-2172. | 2.2 | 7 |
| 629 | Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639. | 3.0 | 7 |
| 630 | Hepatitis delta in patients hospitalized in Spain (1997-2018). <i>Aids</i> , 2021, 35, 2311-2318. | 2.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 631 | Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. <i>Aids</i> , 2022, 36, 249-256. | 2.2 | 7 |
| 632 | Detection of HTLV-II proviral sequences in HIV-immunosuppressed patients with HTLV indeterminate serological patterns. <i>Journal of Infection</i> , 1998, 36, 243-244. | 3.3 | 6 |
| 633 | Role of Nucleosides in the Development of HAART-Related Lipid Disturbances. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 496-498. | 2.1 | 6 |
| 634 | Liver Biopsy in HIV-Infected Patients with Chronic Hepatitis C: Pros and Cons. <i>HIV Clinical Trials</i> , 2002, 3, 351-353. | 2.0 | 6 |
| 635 | How effective is HAART in HCV and HIV coinfection?. <i>Aids</i> , 2004, 18, 2081-2084. | 2.2 | 6 |
| 636 | Influence of HTLV-2 infection on hepatitis C virus replication in HIV-positive patients. <i>Journal of Clinical Virology</i> , 2005, 32, 338-339. | 3.1 | 6 |
| 637 | Lack of anti-HIV activity of entecavir in an HIV patient coinfecting with hepatitis B and delta viruses. <i>Aids</i> , 2007, 21, 2253-2254. | 2.2 | 6 |
| 638 | Short Communication:HIV Rebound after Discontinuation of Antiretroviral Therapy Increases and Expands HIV-Specific CD8+Responses But Has No Impact on Its Functionality. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1197-1201. | 1.1 | 6 |
| 639 | HIV-1 Infection in Persistently HIV-1-Seronegative Individuals: More Reasons for HIV RNA Screening. <i>Clinical Infectious Diseases</i> , 2008, 46, 785-785. | 5.8 | 6 |
| 640 | Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4153-4158. | 3.2 | 6 |
| 641 | Update on HIV viral-load assays: new technologies and testing in resource-limited settings. <i>Future Virology</i> , 2009, 4, 423-430. | 1.8 | 6 |
| 642 | Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 398-410. | 3.0 | 6 |
| 643 | Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 419-424. | 1.1 | 6 |
| 644 | Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain. <i>Journal of Clinical Virology</i> , 2011, 51, 192-194. | 3.1 | 6 |
| 645 | Prevalence of Xenotropic Murine Leukemia Virus-Related Virus Infection in Different Risk Populations in Spain. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1089-1094. | 1.1 | 6 |
| 646 | Liver fibrosis progression in HIV+HCV-coinfected patients treated with distinct antiretroviral drugs and impact of peginterferon-ribavirin therapy. <i>Antiviral Therapy</i> , 2013, 19, 287-292. | 1.0 | 6 |
| 647 | TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfecting patients. <i>Journal of Clinical Virology</i> , 2015, 65, 62-67. | 3.1 | 6 |
| 648 | High Serum HCV RNA in Chronic Hepatitis C Patients Coinfected with HIV despite Successful Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2016, 21, 489-494. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 649 | Need to Face Liver Cirrhosis after HCV Cure with Antivirals. <i>EBioMedicine</i> , 2017, 24, 24-25. | 6.1 | 6 |
| 650 | Impact of <i>ITPA</i> Gene Polymorphisms on the Risk of Ribavirin-Induced Haemolytic Anaemia using Interferon-Free Antivirals for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2017, 22, 571-575. | 1.0 | 6 |
| 651 | Short Communication: Impact of COVID-19 on Case Reporting for HTLV and HIV-2 in Spain. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 610-612. | 1.1 | 6 |
| 652 | Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. <i>PLoS ONE</i> , 2017, 12, e0184329. | 2.5 | 6 |
| 653 | Unveiling Long COVID-19 Disease. <i>AIDS Reviews</i> , 2021, 22, 227-228. | 1.0 | 6 |
| 654 | Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies. <i>Journal of Viral Hepatitis</i> , 2022, 29, 777-784. | 2.0 | 6 |
| 655 | Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. <i>Future Microbiology</i> , 2022, 17, 887-897. | 2.0 | 6 |
| 656 | Evaluation of a New Fluorescence Immunoassay for CD4+ and CD8+ T Cell Counts in Clinical Samples. <i>Vox Sanguinis</i> , 1994, 67, 86-87. | 1.5 | 5 |
| 657 | Serial Dilutions on Synthetic Peptide-Based Assays Can Resolve Dual Seroreactivity to HIV-1 and HIV-2. <i>Vox Sanguinis</i> , 1996, 71, 67-68. | 1.5 | 5 |
| 658 | Genetic Analysis of an HIV Type 2 Subtype B Virus from a Spanish Individual with AIDS. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 899-900. | 1.1 | 5 |
| 659 | Letter to the Editor: Phylogenetic Analysis of HIV Type 2 Strains from Portugal. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 471-473. | 1.1 | 5 |
| 660 | Human T-cell Leukemia/Lymphoma Virus Type II Infection in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 75-76. | 2.9 | 5 |
| 661 | Intensification of Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 499-506. | 1.1 | 5 |
| 662 | Atazanavir: The Advent of a New Generation of More Convenient Protease Inhibitors. <i>HIV Clinical Trials</i> , 2005, 6, 50-61. | 2.0 | 5 |
| 663 | Host genetics. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 491-500. | 3.8 | 5 |
| 664 | A New Era for Hepatitis C – New Diagnostics Tools and New Weapons. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 440-441. | 2.8 | 5 |
| 665 | Very Late HCV Relapse following Triple Therapy for Hepatitis C. <i>Antiviral Therapy</i> , 2014, 19, 723-724. | 1.0 | 5 |
| 666 | HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2191-2194. | 3.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 667 | PPAR β 2 Pro12Ala Polymorphism Is Associated With Sustained Virological Response in HIV/HCV-Coinfected Patients Under HCV Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 113-119. | 2.1 | 5 |
| 668 | European mitochondrial haplogroups are not associated with hepatitis C virus (<scp>HCV</scp>) treatment response in <scp>HIV</scp>/<scp>HCV</scp>-coinfected patients. <i>HIV Medicine</i> , 2014, 15, 425-430. | 2.2 | 5 |
| 669 | <i>IL15</i> polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. <i>Liver International</i> , 2016, 36, 1258-1266. | 3.9 | 5 |
| 670 | Acute hepatitis C virus re-infection in a heterosexual <scp>HIV</scp>-positive partner. <i>Liver International</i> , 2016, 36, 763-763. | 3.9 | 5 |
| 671 | V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection. <i>Aids</i> , 1999, 13, 532. | 2.2 | 5 |
| 672 | Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. <i>Aids</i> , 2000, 14, 1659-1660. | 2.2 | 5 |
| 673 | Toxicidad mitocondrial de los antirretrovirales: diagnóstico y monitorización. <i>Medicina Clínica</i> , 2003, 121, 310-315. | 0.6 | 5 |
| 674 | ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. <i>PLoS ONE</i> , 2015, 10, e0144004. | 2.5 | 5 |
| 675 | Caution with new oral hepatitis C drugs. <i>AIDS Reviews</i> , 2015, 17, 121-2. | 1.0 | 5 |
| 676 | Report from the International Conference on Viral Hepatitis - 2017. <i>AIDS Reviews</i> , 2018, 20, 58-70. | 1.0 | 5 |
| 677 | Hepatitis B Gene Therapy Coming to Age. <i>AIDS Reviews</i> , 2018, 20, 125-127. | 1.0 | 5 |
| 678 | HTLV-II Infection among Immigrants to Spain. <i>Vox Sanguinis</i> , 1994, 67, 79-80. | 1.5 | 4 |
| 679 | Idiopathic CD4+ T Lymphocytopenia: A Review and Current Perspective. <i>Transfusion Medicine Reviews</i> , 1994, 8, 223-231. | 2.0 | 4 |
| 680 | Absence of evidence of retroviral infection in idiopathic CD4+ T-lymphocytopenia syndrome. <i>Aids</i> , 1994, 8, 267. | 2.2 | 4 |
| 681 | Avoiding false-negative results for HTLV-II using new serological assays. <i>American Journal of Medicine</i> , 1995, 98, 103. | 1.5 | 4 |
| 682 | Prevalence of the HIV Protease Mutation N88S Causing Hypersensitivity to Amprenavir. <i>Clinical Infectious Diseases</i> , 2002, 34, 1288-1289. | 5.8 | 4 |
| 683 | Rapid Assessment of Phenotypic Resistance to Protease Inhibitors in Human Immunodeficiency Virus Type 1 Group O. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4313-4316. | 3.9 | 4 |
| 684 | Transmission of HIV Type 1 through Blood Transfusion from an Antibody-Negative/p24 Antigen-Negative Donor. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 447-448. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 685 | Hepatitis B Virus Infection Despite Receiving Lamivudine in One HIV-Infected Person. <i>HIV Clinical Trials</i> , 2003, 4, 77-78. | 2.0 | 4 |
| 686 | Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. <i>Aids</i> , 2004, 18, 689-690. | 2.2 | 4 |
| 687 | CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1141-1147. | 3.0 | 4 |
| 688 | The expansion ability but not the quality of HIV-specific CD8+ T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors. <i>Immunology</i> , 2011, 134, 305-313. | 4.4 | 4 |
| 689 | A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 915-921. | 3.0 | 4 |
| 690 | High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. <i>HIV Medicine</i> , 2014, 15, n/a-n/a. | 2.2 | 4 |
| 691 | A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , 2014, 42, 757-762. | 4.7 | 4 |
| 692 | Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs. <i>Virology Journal</i> , 2015, 12, 4. | 3.4 | 4 |
| 693 | Is HIV still a special population for the treatment of hepatitis C?. <i>Aids</i> , 2016, 30, 2001-2003. | 2.2 | 4 |
| 694 | Antiretroviral treatment of HIV-2 infection. <i>Future Virology</i> , 2017, 12, 461-472. | 1.8 | 4 |
| 695 | Keeping alive enterprises while embracing unprecedented COVID-19 restrictions. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612092017. | 1.8 | 4 |
| 696 | COVID-19 Comes 40 Years After AIDS - Any Lesson?. <i>AIDS Reviews</i> , 2021, 22, 63-77. | 1.0 | 4 |
| 697 | Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 207. | 2.2 | 4 |
| 698 | Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine. <i>Aids</i> , 2001, 15, 2469-2470. | 2.2 | 4 |
| 699 | Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations. <i>Aids</i> , 2003, 17, 442-444. | 2.2 | 4 |
| 700 | Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients. <i>Aids</i> , 2003, 17, 919-921. | 2.2 | 4 |
| 701 | Reactivation of Hepatitis B in HIV Patients Treated for Hepatitis C. <i>AIDS Reviews</i> , 2016, 18, 222-223. | 1.0 | 4 |
| 702 | HTLV-1 Infection is Rising Up in Spain Whereas HTLV-2 is Vanishing. <i>AIDS Reviews</i> , 2019, 21, 233-235. | 1.0 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 703 | Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clinical Trials, 2002, 3, 249-57. | 2.0 | 4 |
| 704 | Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatology International, 2022, 16, 1161-1169. | 4.2 | 4 |
| 705 | Treatment of hepatitis delta and <scp>HIV</scp> infection. Liver International, 2023, 43, 108-115. | 3.9 | 4 |
| 706 | Insufficiencies of the New WHO Western Blot Criteria in the Diagnosis of HIVâ€1 and HIVâ€2 Infections. Vox Sanguinis, 1992, 62, 191-192. | 1.5 | 3 |
| 707 | Sequence Analysis of the V1/V2 and V3 Domains in an HIV-Seronegative AIDS Patient. AIDS Research and Human Retroviruses, 1995, 11, 1539-1541. | 1.1 | 3 |
| 708 | Correlation between Serological and Genetic Methods for Typing Hepatitis C Virus. Vox Sanguinis, 1996, 71, 190-191. | 1.5 | 3 |
| 709 | CCR5 Genotype and Human Immunodeficiency Virus Typeâ€1 Infection in Perinatally Exposed Infants. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 389-391. | 2.9 | 3 |
| 710 | Motivo de ingreso hospitalario en pacientes con infecciÃ³n por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. Medicina ClÃnica, 2002, 119, 293-295. | 0.6 | 3 |
| 711 | Impact of Hepatitis C Virus (HCV) on Morbidity and Mortality Rates among HIV-Infected Patients. Clinical Infectious Diseases, 2003, 37, 460-461. | 5.8 | 3 |
| 712 | Replacement of Protease Inhibitors by Nevirapine or Efavirenz in Simplification and Rescue Interventions: Which Works Better?. HIV Clinical Trials, 2003, 4, 244-247. | 2.0 | 3 |
| 713 | Modifications in SENV DNA Detection and/or SENV Subtype Determination over a Prospective Follow-Up in a Cohort of HIV-Positive Patients: Is This a Moving Target?. Intervirology, 2004, 47, 350-354. | 2.8 | 3 |
| 714 | <i>Short Communication:</i> Association between Tipranavir Plasma Levels and Virological Response in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2008, 24, 389-391. | 1.1 | 3 |
| 715 | Initial spontaneous clearance and re-infection with a distinct hepatitis C virus genotype leading to chronic hepatitis C in an HIV+ intravenous drug user. Aids, 2008, 22, 318. | 2.2 | 3 |
| 716 | Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2009, 27, 28-32. | 0.5 | 3 |
| 717 | The role of injection versus socioeconomic factors in hepatitis A virus infection among young heroin users: Implications for vaccination policies. Vaccine, 2009, 27, 2674-2679. | 3.8 | 3 |
| 718 | Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. Journal of Viral Hepatitis, 2011, 18, 542-548. | 2.0 | 3 |
| 719 | Cardiovascular Disease Risk in HIV Infection and Endothelial Progenitor Cells. Journal of Infectious Diseases, 2012, 206, 1479-1480. | 4.0 | 3 |
| 720 | Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. Current Hepatitis Reports, 2013, 12, 269-275. | 0.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 721 | Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377. | 3.3 | 3 |
| 722 | The Resurgence of Medical Ethics During the Coronavirus Disease (COVID)-19 Outbreak. <i>AIDS Reviews</i> , 2020, 22, 123-124. | 1.0 | 3 |
| 723 | Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir. <i>Aids</i> , 1997, 11, 1896-1897. | 2.2 | 3 |
| 724 | Rapid antigen Testing and Mask Wearing While Waiting for COVID-19 Vaccines. <i>AIDS Reviews</i> , 2020, 22, 168-172. | 1.0 | 3 |
| 725 | Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612098212. | 1.8 | 3 |
| 726 | RNA viruses at the forefront of human infections - HIV, hepatitis C, and now Ebola. <i>AIDS Reviews</i> , 2014, 16, 246-7. | 1.0 | 3 |
| 727 | Transmission of Multi-Drug Resistant HIV-1 Despite Antiretroviral Prophylaxis. <i>AIDS Reviews</i> , 2017, 19, 54-55. | 1.0 | 3 |
| 728 | Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process. <i>HIV Medicine</i> , 2022, 23, 639-649. | 2.2 | 3 |
| 729 | Synthetic Peptide Immunoassay for Diagnosis of HIV 2 Infection. <i>Vox Sanguinis</i> , 1989, 57, 222-222. | 1.5 | 2 |
| 730 | Significance of Positive Polymerase Chain Reaction Results in HIV-1 Seronegative Individuals. <i>Vox Sanguinis</i> , 1992, 63, 287-288. | 1.5 | 2 |
| 731 | Prophylaxis of <i>Pneumocystis carinii</i> pneumonia. <i>Aids</i> , 1993, 7, 1133. | 2.2 | 2 |
| 732 | Circulating HIV-1 Serotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 236-237. | 1.5 | 2 |
| 733 | Sequence Note: Genetic Analysis of Human Immunodeficiency Virus Type 2 Strains from Spain. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 91-94. | 1.1 | 2 |
| 734 | Carga viral y valores de linfocitos CD4+ en la era de la terapia antirretroviral altamente potente. <i>Medicina Clínica</i> , 2000, 115, 118. | 0.6 | 2 |
| 735 | Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations. <i>Journal of Clinical Microbiology</i> , 2004, 42, 862-866. | 3.9 | 2 |
| 736 | Complications in treating chronic hepatitis B in patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2831-2842. | 1.8 | 2 |
| 737 | Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients. <i>Aids</i> , 2007, 21, 652-653. | 2.2 | 2 |
| 738 | Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years. <i>Aids</i> , 2008, 22, 1371-1374. | 2.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 739 | 648 DIFFERENCES IN ANTIVIRAL ACTIVITY AND TOLERABILITY BETWEEN PEGYLATED INTERFERON ALPHA 2A AND 2B IN HIV INFECTED PATIENTS WITH CHRONIC HEPATITIS C. Journal of Hepatology, 2009, 50, S238-S239. | 3.7 | 2 |
| 740 | Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes. Journal of Viral Hepatitis, 2010, 17, 866-871. | 2.0 | 2 |
| 741 | Short Communication: RNASEL Alleles and Susceptibility to Infection by Human Retroviruses and Hepatitis Viruses. AIDS Research and Human Retroviruses, 2012, 28, 1259-1261. | 1.1 | 2 |
| 742 | Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure. AIDS Research and Therapy, 2012, 9, 23. | 1.7 | 2 |
| 743 | Long-Term Use of Atazanavir in the Treatment of HIV-Infected patients. Clinical Medicine Insights Therapeutics, 2012, 4, CMT.S5764. | 0.4 | 2 |
| 744 | No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients. Antiviral Research, 2012, 95, 67-71. | 4.1 | 2 |
| 745 | Is Ribavirin Teratogenic in Humans? No Evidence So Far. Drug Safety, 2017, 40, 1163-1165. | 3.2 | 2 |
| 746 | JÃ©rÃ©me Lejeune passed away 25 years ago. Hereditas, 2019, 156, 18. | 1.4 | 2 |
| 747 | Tough requirements for new antiretroviral drugs. Lancet HIV, 2020, 7, e150-e151. | 4.7 | 2 |
| 748 | Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections. AIDS Reviews, 2020, 22, 124-127. | 1.0 | 2 |
| 749 | Use of antibiotics in respiratory viral infections. Internal and Emergency Medicine, 2022, 17, 1569-1570. | 2.0 | 2 |
| 750 | HIV-2 Infection in high-risk individuals in Spain. Transfusion Science, 1993, 14, 167-172. | 0.6 | 1 |
| 751 | Kussmaul respiration and abdominal pain secondary to metabolic acidosis in AIDS patients with disseminated Mycobacterium avium complex infection receiving clofazimine. Aids, 1993, 7, 894. | 2.2 | 1 |
| 752 | Co-infection with several HCV genotypes enhances liver damage in patients with chronic hepatitis C. Journal of Infection, 1997, 35, 202-203. | 3.3 | 1 |
| 753 | Is there a role for indinavir twice-daily in clinical practice?. Clinical Microbiology and Infection, 2000, 6, 152-154. | 6.0 | 1 |
| 754 | Response to Drs. Toyoda et al.. American Journal of Gastroenterology, 2001, 96, 3441-3442. | 0.4 | 1 |
| 755 | ¿Se deberÃ­a recomendar el cribado de la infecciÃ³n por el virus linfotrópico humano de células T de tipo 1 en las mujeres embarazadas?. Progresos En Obstetricia Y Ginecologia, 2006, 49, 523-525. | 0.0 | 1 |
| 756 | Chronic Hepatitis C in HIV-Infected Patients: Those Who More Need Therapy are Those Who Respond Less. Infectious Disorders - Drug Targets, 2006, 6, 57-68. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 757 | Management and therapy of chronic hepatitis C in HIV. Current Opinion in HIV and AIDS, 2007, 2, 482-488. | 3.8 | 1 |
| 758 | Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008. HIV Clinical Trials, 2008, 9, 348-365. | 2.0 | 1 |
| 759 | Differences in Lopinavir Plasma Concentrations Comparing Kaletra® Film Coated Tablets and Soft Gelatine Capsules That Result in Various Lipid Abnormalities. Drug Metabolism Letters, 2009, 3, 67-69. | 0.8 | 1 |
| 760 | Resistance data in the ARTEN trial. Antiviral Therapy, 2011, 16, 1135-1136. | 1.0 | 1 |
| 761 | HCV and HIV Coinfection. Current Hepatitis Reports, 2011, 10, 52-61. | 0.3 | 1 |
| 762 | Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. European Journal of Gastroenterology and Hepatology, 2016, 28, 923-926. | 1.6 | 1 |
| 763 | SOLAR-2: the sun also rises for cirrhotics. Lancet Infectious Diseases, The, 2016, 16, 624-625. | 9.1 | 1 |
| 764 | Hepatitis Delta Estimates in the United States Revisited. Clinical Infectious Diseases, 2019, 69, 1833-1834. | 5.8 | 1 |
| 765 | Clinical Outcome in Human T-Lymphotropic Virus Type 2 Carriers Following Organ Transplantation. Transplantation Proceedings, 2021, 53, 743-745. | 0.6 | 1 |
| 766 | Situación epidemiológica actual de la infección por VIH-2 y HTLV-1 en España. Medicina Clínica, 2021, 156, 290-296. | 0.6 | 1 |
| 767 | Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health. Journal of Virus Eradication, 2018, 4, 196-207. | 0.5 | 1 |
| 768 | Report from the International Conference on Viral Hepatitis (ICVH), San Francisco, March 2016. AIDS Reviews, 2016, 18, 81-8. | 1.0 | 1 |
| 769 | A New HIV Paradigm: Dual Antiretroviral Regimens as Maintenance Therapy. AIDS Reviews, 2017, 19, 113-114. | 1.0 | 1 |
| 770 | Serological Markers of Human Immunodeficiency Virus Infection in African Patients with AIDS: Are They Different from Markers Found in Patients from Other Countries?. Journal of Infectious Diseases, 1988, 158, 894-894. | 4.0 | 0 |
| 771 | HIV-2 in Spanish Drug Abusers. Vox Sanguinis, 1989, 57, 157-157. | 1.5 | 0 |
| 772 | Non-Parenteral Transmission of Hepatitis C Virus. International Journal of STD and AIDS, 1991, 2, 449-450. | 1.1 | 0 |
| 773 | Human Herpesvirus 6 in Spain: Seroprevalence in Blood Donors and Patients with Lymphoproliferative Disorders or HIV Infection. Vox Sanguinis, 1991, 60, 63-64. | 1.5 | 0 |
| 774 | Hepatitis C Virus Genotypes 1a and 1b Mixed Infections. Vox Sanguinis, 1997, 72, 64-64. | 1.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 775 | Association Between Submaximal Suppression of HIV Replication and Use of Drug Combinations Without Protease Inhibitors. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 604-605. | 2.9 | 0 |
| 776 | Tolerability of Abacavir in the clinical setting. <i>Clinical Microbiology and Infection</i> , 2000, 6, 621-622. | 6.0 | 0 |
| 777 | Response to Drs. Toyoda et al.. <i>American Journal of Gastroenterology</i> , 2001, 96, 3441-3442. | 0.4 | 0 |
| 778 | Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in HIV-infected patients. <i>Journal of Hepatology</i> , 2002, 36, 107. | 3.7 | 0 |
| 779 | Efficacy and safety of combination therapy with interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 108. | 3.7 | 0 |
| 780 | Reply to Bruno et al.. <i>Aids</i> , 2004, 18, 2102-2103. | 2.2 | 0 |
| 781 | Phage Display Selection of HIV Specific Conserved Mimotopes With IgG from Long-term Non-progressors. <i>Retrovirology</i> , 2005, 2, P29. | 2.0 | 0 |
| 782 | Standard of Care for HCV/HIV-Coinfected Patients. <i>Journal of Chemotherapy</i> , 2006, 18, 21-26. | 1.5 | 0 |
| 783 | Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption. <i>Retrovirology</i> , 2010, 7, . | 2.0 | 0 |
| 784 | Glomerular filtration (GF) determined by creatinine clearance (CCR) in 24 hours urine and cockcroft & gault (cg) and modification of diet in renal disease (MDRD) equations in a large cohort of HIV+ patients. <i>Retrovirology</i> , 2010, 7, . | 2.0 | 0 |
| 785 | High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists—authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2057-2058. | 3.0 | 0 |
| 786 | HIV and Liver Disease. <i>Seminars in Liver Disease</i> , 2012, 32, 101-102. | 3.6 | 0 |
| 787 | B3&fIdentification of Neutralizing Antibodies and Their Epitopes From HIV Controllers. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 74. | 2.1 | 0 |
| 788 | Author's response: expert reviews: who are they for?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1217-1218. | 1.8 | 0 |
| 789 | P750 SPONTANEOUS HCV CLEARANCE IN HIV PATIENTS WITH CHRONIC HEPATITIS C BEARING FAVORABLE IL28B ALLELES ON ANTIRETROVIRAL THERAPY. <i>Journal of Hepatology</i> , 2014, 60, S321. | 3.7 | 0 |
| 790 | Corrigendum. <i>HIV Clinical Trials</i> , 2015, 16, 236-238. | 2.0 | 0 |
| 791 | Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID). <i>Journal of Virus Eradication</i> , 2016, 2, 187-192. | 0.5 | 0 |
| 792 | Delta hepatitis: new approaches to therapy. <i>Future Virology</i> , 2016, 11, 197-205. | 1.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 793 | Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy. AIDS Research and Human Retroviruses, 2016, 32, 226-231. | 1.1 | 0 |
| 794 | Human T-Lymphotropic Virus Infection in Hepatitis C Virus Antibody Positive Patients in Spain. AIDS Research and Human Retroviruses, 2017, 33, 1013-1017. | 1.1 | 0 |
| 795 | Current epidemiological status of HIV-2 and HTLV-1 infection in Spain. Medicina Clínica (English) 2021; 156: 578-582. Tj ETQq1 1 0.784314 rgBT /Overl | 0.2 | 0 |
| 796 | Considerations on HTLV-1 infection in Spain. Medicina Clínica (English Edition), 2021, 156, 578. | 0.2 | 0 |
| 797 | COVID-19 in Madrid: Leading Pandemic Control after being the Spanish Epicenter. AIDS Reviews, 2021, 23, 115-116. | 1.0 | 0 |
| 798 | Consideraciones sobre la infección por HTLV-1 en España. Medicina Clínica, 2021, 156, 578. | 0.6 | 0 |
| 799 | The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2010, 32, 242-244. | 2.0 | 0 |
| 800 | A Key Action Plan for EDUCATION in a Global Crisis. Lecture Notes in Educational Technology, 2021, , 263-272. | 0.8 | 0 |
| 801 | Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): 25-27 May, Marseille, France. Journal of Virus Eradication, 2016, 2, 187-92. | 0.5 | 0 |
| 802 | Another patient has cured HIV infection. AIDS Reviews, 2022, 23, 226-227. | 1.0 | 0 |
| 803 | Non-Human Cancers in AIDS Patients. AIDS Reviews, 2015, 17, 238-9. | 1.0 | 0 |
| 804 | Acute Viral Hepatitis in Men Having Sex with Men. AIDS Reviews, 2020, 22, 168-172. | 1.0 | 0 |
| 805 | A greater virulent HIV-1 subtype B variant has circulated in The Netherlands since the 1990s. AIDS Reviews, 2022, 24, 50. | 1.0 | 0 |
| 806 | The unexpected high prevalence of HBV subgenotype D4 in patients with chronic hepatitis B in Galicia, a northwestern Spanish region, reflects strong links with Latin America. Journal of Clinical Virology, 2022, 153, 105195. | 3.1 | 0 |